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ABSTRACT                                                             English 
The scientific community has become increasingly interested in understanding what 
lies behind the continuing extension of the human lifespan. The main aim of this thesis 
was to better understand the association between health status, lifestyle, genetic factors 
and survival in advanced age. Data used in the 4 studies are gathered from the 
Kungsholmen Project, a longitudinal population-based study on 75 year and older 
participants living in Stockholm, Sweden. 
Study I. Dementia, cardiovascular disease (CVD), and cancer were associated with a 2- 
to 3-fold increased rate of all-cause mortality. The mean survival times after incident 
diagnosis were 4.1 years for dementia, 4.2 years for CVD, and 2.2 years for cancer. A 
total of 3.4 potential years of life were lost because of dementia, 3.6 of CVD, and 4.4 
because of cancer. Women aged 75 to 84 years lived longer than coetaneous men after 
incident diagnosis of dementia because they spent 1.6 years longer than men in the 
severe stage of the disease. 
Study II. Findings suggest that APOE alleles play different roles in the survival of 
elderly women and men. The mortality rate was 40% lower among women, but not 
men, who carried the ε2 allele, compared with the ε3ε3 carriers. The ε4 allele was 
associated with a 50% higher rate of death only among men. Dementia, not ischemic 
heart and cerebrovascular diseases, accounted for the majority of the increased 
mortality rate in those with the ε4 allele. 
Study III. Maintaining a healthy lifestyle and a rich social network was positively 
associated with survival even among people aged 75 years and older. People who 
reported being physically active a minimum of once a month lived about 2 years longer 
than those who did not. Non-smokers 75 years and older who participated in at least 1 
leisure activity a month and had good social support lived about 5 years longer than 
inactive smokers with poor social support. These association, although attenuated, 
were also found in individuals aged 85 years and older and those with chronic diseases. 
Study IV. Genetic risk factors were relevant for survival after age 75. Variations in 4 
different genes (APOC1, APOE, IDE, and PI3K) were associated with 12–20% 
increased rate of mortality. However, participants with at least 1 risk allele and a 
healthy lifestyle had about 70% lower rate of death than those with no risk allele and an 
unhealthy lifestyle. Those with no risk alleles and a healthy lifestyle had 80% lower 
mortality rate and 6 years longer median lifespan than people with at least 1 risk allele 
and unhealthy lifestyle. 
In conclusion, survival after 75 years of age was associated with health status, lifestyle, 
genetic factors, and a combination of those factors. These findings may help prognostic 
evaluation of the duration of specific diseases. They underscore the malignant nature of 
dementia as a result of the long period individuals lived with the severe disease stages, 
especially for women. These findings also suggest that the benefit of a healthy 
lifestyle, healthy behavior, and social support probably last a lifetime. Moreover, 
allelic variations in genes were associated with higher mortality rate, but the 
combined effect of genetic-environmental joint exposures may lead to the attenuation 
of the mortality rate, indicating that people with genetic susceptibility may reduce 
their initial mortality rate by modifying their lifestyle. Therefore, efforts to encourage 
smoking cessation, physical activity, and social engagement should be continued long 
into late life. 
Key words: Mortality, age-related chronic diseases, lifestyle factors, genetic factors. 
 SAMMANFATTNING                                          SVENSKA 
Det finns ett stort intresse för att förstå de mekanismer som får människor att leva 
längre och längre. Syftet med denna avhandling är att öka förståelsen för sambanden 
mellan hälsa, livsstil, genetiska faktorer och överlevnad till hög ålder. Data till de 4 
studierna kommer från Kungsholms projektet, en longitudinell studie av personer 75 år 
eller äldre, boende i Stockholm, Sverige.  
Studie I. Demens, kardiovaskulära sjukdomar, and cancer var i den första studien 
associerade med en 2–3 faldig ökad risk för dödlighet. Antal år som personerna 
överlevde efter att de fått en diagnos var i medel 4,2 år för de med demens, 4,2 år för de 
med kardiovaskulär sjukdom och 4,2 år för de med cancer. Livet förkortades 3,4 år för 
personer med demens, 3,6 år för personer med kardiovaskulär sjukdom och 4,4 för 
personer med cancer. Kvinnor i åldern 75-84 levde längre efter att de fått en 
demensdiagnos än män i samma ålder, beroende på att de levde 1,6 år längre i ett 
senare och mera avancerat stadium av sjukdomen.  
Studie II. Denna studie visar att variationer i APOE har olika betydelse för 
överlevnad hos kvinnor och män. Dödligheten var 40% lägre hos kvinnor, men ej hos 
män, som bar på APOE ε2. ε4 allelen var associerad med 50% högre risk för död 
enbart hos män. Demens var den faktor som förklarade majoriteten av den ökade risken 
för död hos ε4-bärare, medan kardiovaskulär sjukdom inte alls förklarade den ökade 
risken. 
Studie III. Upprätthållandet av en hälsosam livsstil och ett rikt socialt nätverk hade 
ett positivt samband med överlevnad för personer som var 75 år och äldre. Personer 
som rapporterade att de var fysiskt aktiva åtminstone en gång per månad, levde 
ungefär 2 år längre än de som inte var fysiskt aktiva. Icke-rökare, 75 år och äldre, 
som deltog i åtminstone en fritidsaktivitet varje månad, och som hade ett bra socialt 
närverk, levde ungefär 5 år längre än rökare, som inte hade någon fritidsaktivitet och 
som hade ett dåligt socialt närverk. Detta kunde också observeras hos de som var 85 
år och äldre, med kroniska sjukdomar, men effekten var försvagad hos denna grupp. 
Studie IV. Genetiska riskfaktorer påverkade överlevnaden efter 75 års ålder. 
Variaitoner i 4 gener (APOC1, APOE, IDE och PI3K) visade 12–20% ökad risk för 
dödlighet. Trots det hade personer med minst en riskallel och en hälsosam och aktiv 
livsstil ungefär 70% lägre risk än de utan någon riskallel och en ohälsosam och inaktiv 
livsstil. Personer utan de genetiska riskfaktorerna och med en hälsosam och aktiv 
livsstil hade 80% lägre risk för att dö och medianvärdet för livslängden var 6 år längre 
än för de som bar på minst en riskallel och hade en ohälsosam och inaktiv livsstil.  
Sammanfattningsvis är sannolikheten att leva längre än till 75 års ålder beroende av 
hälsostatus, livsstil, genetiska faktorer och en kombination av alla dessa faktorer. 
Fynden som presenteras i denna avhandling kan komma till nytta vid prognostiska 
utvärderingar av durationen specifika sjukdomar. De understryker demenssjukdomars 
elakartade karaktär, som följd av den långa tid människor lever i den allvarligaste och 
svåraste fasen av sjukdomen. Detta var speciellt uttalat för kvinnor. Dessa fynd pekar 
också på vikten av en hälsosam livsstil, ett hälsosamt beteende och ett fungerande 
socialt närverk för att leva länge. Det fanns ett samband mellan genetiska variationer 
och dödlighet, men resultaten indikerar att denna effekt kunde modifieras genom en 
hälsosammare livsstil. Slutsatsen är att ett hälsosamt leverne, så som att sluta röka, leva 
fysiskt aktivt och med ett socialt engagemang ska uppmuntras högt upp i åldrarna.  
Nyckelord: Dödlighet, åldersrelaterade sjukdomar, livsstilsfaktorer, genetiska faktorer. 
RIASSUNTO                                                        ITALIANO 
L’aumento dell’aspettativa di vita riveste un notevole interesse nell’ambito scientifico. 
L'obiettivo principale di questa tesi viene perseguito attraverso l’esame epidemiologico 
dell’associazione tra stato di salute, lo stile di vita e i fattori genetici da un lato, e 
probabilità di vivere oltre i 75 anni dall’altro. I dati sono tratti dal Kungsholmen 
Project, uno studio longitudinale su anziani di 75+ anni residenti a Stoccolma, Svezia. 
Studio I. La diagnosi di demenza, di malattie cardiovascolari (CVD), o di cancro sono 
associate a una probabilità 2–3 volte maggiore di morire. Gli anni potenziali di vita 
persi a causa della demeza sono 3,4, 3,6 per le CVD e 4,4 il cancro. Gli anni medi di 
sopravvivenza dopo la diagnosi delle malattie sono 4,1 per la demenza, 4,2 per le CVD, 
e 2,2 per il cancro. Dopo la diagnosi di demenza le donne di 75–84 anni vivono più a 
lungo rispetto agli uomini coetanei. Infatti, sopravvivono 1,6 anni in più nella fase più 
grave della malattia. 
Studio II. I risultati suggeriscono che le variazioni genetiche dell’APOE hanno un 
effetto opposto sulla sopravvivenza degli uomini e delle donne. Confrontato con il 
genotipo ε3ε3, l'allele ε2 è un fattore protettivo della mortalità (40% più basso) per le 
donne, ma non per gli uomini. L'allele ε4, invece, è un fattore di rischio di morte 
(50% più elevato) solo tra gli uomini. L’aumento del rischio di morte per le persone 
portatrici dell’allele ε4 è dovuto maggiormente allo sviluppo della demenza, ma non 
delle malattie cardiovascolari. 
Studio III. Essere attivi e avere uno stile di vita sano anche a 75 anni può fare la 
differenza. Le persone che fanno attività fisica almeno una volta al mese hanno una 
aspettativa mediana di vita più lunga di circa 2 anni, rispetto alle persone sedentarie. 
L’aspettativa mediana di vita per i non fumatori che hanno una vita attiva è di 5 anni 
più lunga rispetto alle persone con una vita sedentaria e uno stile di vita non sano. 
Vita attiva e buone abitudini producono l’effetto di allungamento della vita anche su 
persone di 85 anni e in generale sui malati. 
Studio IV. I fattori genetici hanno un ruolo rilevante nella sopravvivenza dopo i 75 
anni. Variazioni genetiche in 4 diversi geni (APOC1, APOE, IDE e PI3K) sono 
associate a una mortalità maggiore del 12–20%. Tuttavia i partecipanti con un profilo 
genetico sfavorevole (portatori di almeno un allele associato con la mortalità) ma con 
uno stile di vita sano hanno un rischio di morte circa 70% più basso. Inoltre, la 
combinazione di un profilo genetico favorevole (assenza degli alleli associate con la 
mortalità) con uno stile di vita sano diminuisce dell’80% il rischio di mortalità e 
allunga di 6 anni la durata mediana della vita rispetto a quella delle persone con un 
profilo genetico sfavorevole e uno stile di vita non sano.  
In conclusione, la probabilità di sopravvivere oltre i 75 anni risulta fortemente 
associata con lo stato di salute, lo stile di vita e i fattori genetici. Questi risultati 
potrebbero favorire la valutazione prognostica della durata generale delle tre malattie 
sopra nominate. Essi enfatizzano che lo stadio più grave della demenza e quello in cui 
le persone, in particolare le donne, vivono a lungo. Inoltre, le variazioni alleliche nei 
geni sono associate ad un rischio di mortalità più elevato. Tuttavia l'effetto della 
combinazione della predisposizione genetica sfavorevole con fattori ambientali può 
comportare l'attenuazione del rischio di mortalità, in quanto le persone con una 
predisposizione sfavorevole possono ridurre il rischio di mortalità modificando il loro 
stile di vita. Pertanto, gli sforzi per promuovere la cessazione del fumo, l’attività fisica 
e l'impegno sociale devono essere continuati anche in età avanzata. 
Parole chiave: Mortalità, malattie croniche, stile di vita, fattori genetici. 
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     Introduction 
 1 
1 INTRODUCTION 
The oldest person ever, according to verifiable records, was a French woman called 
Jeanne Calment, who died in 1997 at the age of 122 years and 164 days.
1
 Such 
exceptionally long lives always make us wonder: What is the secret? Does it lie in the 
genes? What makes the difference? Is it the place where people live or the way they live? 
Is it something they do or something they do not do? Scientists who study aging say that 
the secret probably lies in several factors related to both heredity and environment. This 
introduction provides an overview of the research on longevity, showing the major pieces 
already in place and those that are still missing in the challenging puzzle of aging and 
longevity.  
 
1.1 AGING 
The fact is that we all age. Independently of age, whether young or old, we are aging. 
That is the simplest reality that each human being has to deal with and it is part of our life. 
Distinctions may be made between chronological aging and biological aging or 
senescence. Annual birthday celebrations mark the passage of chronological age, whereas 
senescence is the progressive, cumulative deterioration in function or loss of 
physiological capacity associated with greater chronological age.
2
 However, 
chronological age does not correlate perfectly with functional age; i.e., two people may be 
the same age but differ in their mental and physical capacities. 
When does old age begin? There is no single age at which we can say that people cross 
the threshold into old age. The process of aging is highly complex, begins at the time of 
birth, and continues until death. One commonly accepted definition is that people aged 65 
and older are elderly. Divisions are sometimes made between the young old (65–74 years 
of age), the middle old (75–84 years of age), and the oldest old (85 years of age and 
older). Recently, a new phase has been introduced: the fourth age, which refers to that 
period at the end of life when people have completely lost their independence. The fourth 
age is a direct continuation of the third age, during which chronologically old people still 
live an independent life.
3
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1.1.1 Magnitude and speed of population aging 
The older population (people 60 years and older) is growing at a considerably faster rate 
than the world’s total population (Figure 1).4 Until 1975 the average annual growth rate 
of the number of persons aged 60 and older was similar to the rate of growth for the 
total population (about 1.8%). Since then, the annual growth rate of the older population 
has increased faster than that of the total population and is now around 2.6%‒more than 
twice that of the total population (1.2%). By 2025–2030, projections indicate that the 
population of older people might be growing about 4 times as rapidly as the total 
population.
4
 Because of slowing birth rate, since 1975 the annual growth rate of the total 
population has been declining. This decline is projected to continue in the coming years, 
but the pace of the future change is uncertain. Currently, it is estimated that the annual 
growth rate of the total population will be less than 1% by 2020. This means that world 
population will continue to grow in the 21st century, but at a slower rate than in the 
recent past. 
 
 
Figure 1 Average annual growth rate of the world’s total population and the population 
aged 60 and older, 1950–2050. Source of data: United Nations Department of Economic 
and Social Affairs, Population Division 
 
In absolute terms, there were more than 860 million older people in 2010, over 3 times 
more than in 1950. Over the first half of the current century, the global population aged 
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60 and older is projected to increase 3-fold, reaching 2 billion in 2050.
4
 Figure 2 shows 
the steady rise in the proportion of older persons, from 8% in 1950 to 10% in 1990 and 
12% in 2010. This proportion is expected to reach 22% in 2050 (Source of data: United 
Nations Department of Economic and Social Affairs, Population Division). 
 
 
Figure 2 Percentage of the population 60 years and older worldwide, 1950-2050. 
Source of data: United Nations Department of Economic and Social Affairs, 
Population Division 
 
Currently, Europe has the highest proportion of older persons of all the continents.
4
 
Although the highest proportion of older people is found in the more developed countries, 
the annual growth rate of this age group is higher in the less developed countries. Indeed, 
by 2050, nearly 80% of the world’s older population is expected to live in developing 
countries.
5
 
 
1.1.2 Demographic transition 
Population age structures change when mortality and fertility rates change. Such changes 
in mortality and fertility rates are known as the demographic transition.
6
 The demographic 
transition that we are experiencing is characterized by the change from high to low levels 
of both fertility and mortality rates. The transition involves four stages.  
Human longevity   
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The graph in Figure 3 shows an example of population changes in the Swedish 
population. In 1750, Sweden was a typical European agrarian country in stage 1 of the 
demographic transition. It had high annual crude birth (36 per 1000 people) and death 
rates (27 per 1000 people) and high rates of infectious diseases. The population was 
subject to periodic famine and infant mortality was high. Sweden transitioned to stage 2 
between 1750 and 1850. This period was characterized by a falling death rate due to a 
dramatic reduction in infant and childhood mortality. The birth rate remained high and 
may even have increased because women were healthier. After 1850 the birth rate moved 
downward, catching up with the death rate, and Sweden entered stage 3. This reduction in 
the death rate resulted from Pasteur’s discoveries at the end of the nineteenth century.7 
Moreover, Sweden introduced government-run social security programs between 1930 
and 1940, including national health insurance, employee medial insurance, maternity 
welfare, housing allowances, nursery schools, a children’s health system, and free school 
meals. The government also invested in informational programs on nutrition and health.
8
 
In stage 4 of the demographic transition, birth and the death rates are again similar but 
stabilize at relatively low levels (Source of data: Statistics Sweden). 
 
 
Figure 3 The demographic transition in Sweden: annual crude birth and death 
rates (per 1000) from 1750 to 2011. Source of data: Statistics Sweden 
 
Population pyramids for Sweden in 2011 and 2050 are shown in Figure 4. The pyramids 
depict the number of men (left) and women (right) in thousands in each age group. The 
shift in distribution towards older ages by 2050 is readily apparent. The shape of 
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Sweden’s age-sex pyramids is typical of countries that have already undergone the 
demographic transition from high to low mortality and fertility rates. Both pyramids also 
show the strong preponderance of women over men in later life (Source of data: Statistics 
Sweden).  
 
 
Figure 4 Swedish age-sex pyramid: absolute numbers of inhabitants in Sweden in 
2011 and 2050. Source of data: Statistics Sweden 
 
1.1.3 Life expectancy 
Life expectancy (LE) is the average number of years that a person at a specific age can 
expect to live, assuming that age-specific mortality levels remain constant. 
Over the last 50 years, improvements in standards of living (income, nutrition, education) 
and health care (curative and preventive medicine) have resulted in a significant increase 
in life expectancy for the adult and elderly population. LE continues to rise even in 
countries like Sweden where the overall average life expectancy in 2012 is 81.9 years of 
age. According to Statistics Sweden, a Swedish boy born in 2012 can expect to live 80.0 
years, and a girl, 83.8 years.  
The increase in life expectancy is a relatively new phenomenon in the history of the 
humanity. Although there have been always single individuals who reached old ages, it is 
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only during the last 3 to 4 decades that many people have the chance to live to a very 
advanced age.  
This phenomenon in Sweden is illustrated in Figure 5. The number of centenarians was 
extremely low in the middle of the twentieth century. By 1970 there were 127 
centenarians, a number that increased to 1700 in 2011. Most centenarians are women.  
 
 
Figure 5 Increased in the number of the centenarians (100+) in Sweden. Source of 
data: Statistics Sweden 
 
Has the average life expectancy of humans approached its limit? Since the increase in life 
expectancy has been linear for the past centuries, life expectancy trajectories do not 
appear to be approaching a maximum.
9
 Indeed, a study by Christensen et al., 2009,
10
 
forecasts that more than 50% of babies born since 2000 in most western countries and 
Japan will become centenarians if the life expectancy increases over the past 2 centuries 
continue through the 21st century. 
 
1.1.4 Health of the aging population 
Despite the positive nature of the trend in life expectancy, we must still face the major 
question of how to live, not only longer but also healthier.  
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In Europe, as in many other places, future health status will be strongly influenced by 
population aging. Thus, there is an urgent need to better understand the aging process 
with the ultimate goal of improving the health and quality of life of elderly people. For 
these reasons, several years ago researchers in various countries started population-based 
studies that follow middle-aged and elderly people to trace changes in their health status 
over time and identify factors relevant to better health and quality of life in old age. 
The 20th century saw an epidemiological transition in which a reduction in many 
epidemic infectious diseases was counterbalanced by a steady rise in chronic conditions. 
Many of these conditions are associated with important changes in lifestyle
11
 and are the 
consequence of accumulated exposure to risk factors over a person’s lifetime.12,13 Thus is 
not unusual for a person who has reached retirement age to have at least 2 chronic 
conditions,
14
 and such diseases— i.e. cardiovascular disease, dementia, and cancer—have 
replaced infectious diseases as the main causes of death today. Moreover, these public 
health problems remain largely unresolved. Given the current situation and trends, it 
seems likely the future of health care will be dominated by the challenge of complex 
chronic disorders, especially among elderly people. 
Currently, there are several theories about what is happening and will happen to the health 
of elderly people as the population ages. The compression of morbidity theory was put 
forth by James Fries in 1980. Fries' hypothesis is that the burden of lifetime illness may be 
compressed into a shorter period before the time of death if the age of onset of the first 
chronic infirmity can be postponed.
15
 This hypothesis contrasts with the view that if 
medical progress extends life for persons with chronic and disabling conditions but does 
not reduce the incidence of these conditions, the health of the population will deteriorate 
(the theory of expansion of morbidity).
16
 In 1982, Manton proposed a position between 
the 2 outlined above.
17
 His hypothesis, known as dynamic equilibrium, is that alongside 
the reduction in mortality there will be a reduction in the rate of deterioration of the 
body’s vital organ systems. This could result in more diseases in the population, but the 
diseases will be less severe.  
 
1.1.5 Models of aging and longevity 
Several models with different outcomes have been formulated to attempt to explain aging 
process. These models have different outcomes and categorize possible determinants 
differently. In 2004 Crimmins and Seeman proposed a heuristic model of several 
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potentially interacting pathways of interest in understanding health-related outcomes 
linked to aging.
18
 Health outcomes included mortality, physical and cognitive functioning, 
and cardiovascular disease. Kirkwood, in 2005, proposed a model in which a lifelong 
accumulation of molecular damage underlies the aging process.
19
 As cell defects 
accumulate, the body will express such damage with symptoms, disease, and functional 
impairment. The degree of accumulation is accelerated by stress, environmental risk 
factors, and poor nutrition, and modulated by healthy lifestyle and healthy nutrition. 
According to Ryff and Singer, 2009, health in aging is the result of numerous influences 
that can be divided into 3 broad categories: socio-structural factors, individual-level 
factors, and biological factors.
20
 
In spite of some differences, all models agree that the individual is the central figure in the 
model, together with his/her biological background (including genetics) and his/her life-
long exposure to different risk and protective factors. This life-long process brings an 
accumulation of different degrees of damage to 1 or more organs, which accelerates the 
aging process and promotes functional impairment and morbidity. 
 
1.2 DETERMINANTS OF LONGEVITY 
The word longevity (long life), comes from the Latin word longaevitās. Longevity is the 
capability to survive beyond the species-specific average age at death.
21
 This definition 
involves not only the individual ability to achieve old age but also population-level 
mortality, measured in this case by the mean age at death of the population (or life 
expectancy). Alternative definitions of longevity refer to the period between birth and 
death of an individual; that is, the maximum lifespan actually achieved. 
Current evidence from several studies indicates that longevity reflects a variety of 
underlying factors, including genetics, environmental, and medical factors.
22
 It also 
contains a stochastic component that results from the interaction between individual 
chances of surviving and unpredictable events that occur throughout the life course.
23
 It is 
commonly accepted that genetic background explains around 20–30%24 of the variability 
in longevity, the stochastic component around 20%,
23
 and the environmental factors the 
remaining 50–60% . 
     Introduction 
 9 
It is possible to hypothesize that there are multiple ways to achieve exceptional longevity 
by combining these 3 components.
21
 However, probably none of these factors is necessary 
or sufficient to determine the aging phenotype at the individual level.  
The identification of the possible determinants of human longevity is still an open debate. 
Most previous studies that searched for the determinants of longevity were carried out 
within specific research fields such as genetics, medicine, or demography. The major 
consequence of this discipline-specific approach is that often only a selected number of 
variables are considered which renders the search of determinants of longevity limited. 
Nevertheless, a critical review of the existing literature provides useful indications of the 
possible candidate determinants of longevity.  
 
1.2.1 Gender 
Gender is clearly the main factor to take into account when investigating differential 
longevity. It is widely recognized that women generally live longer than men. In 2011, LE 
was 3.9 years higher in Swedish women than in Swedish men. With the exception of few 
countries, LE at birth is higher for females than males worldwide, as shown in Figure 6. 
In the figure, the difference in LE between genders (gender gap) is also reported in 
number of years. 
 
 
Figure 6 Male and female life expectancy at birth and gender gap in life expectancy, 1950–
2055. Source of data: United Nations Department of Economic and Social Affairs, Population 
Division 
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The reasons for this gender gap are multifactorial and not completely understood.
25-29
 
Several hypotheses have been proposed to explain sex difference in longevity. Major 
putative factors fall into 2 general categories: external (social, cultural, environmental, 
and behavioral), and constitutional (biological and genetic) factors. One hypothesis 
attributes the gender gap to a larger participation of men in labor force.
30
 If this hypothesis 
is valid, nowadays we might expect a decrease in differential mortality rate because of 
improved gender equality. However, women still outlive men today. A second hypothesis 
is that women live longer because they are exposed to a smaller number of risk behaviors. 
Although a gender gap in risk behaviors may have existed in the past, it seems to have 
closed today at least for major risk factors such as smoking. Indeed, according to the 
Statistics Sweden, in 2008 the proportion of smokers was higher among women than men, 
at all ages (Figure 7). Therefore, it is unlikely that lifestyle may fully explain the gap. 
 
 
Figure 7 Male and female proportion of daily smokers in 2008. Source of data: 
Statistics Sweden, Living condition survey 
 
As several studies have shown that female animals of most species live longer than male 
animals, an explanation of the gender difference in human LE might lie deep in our 
biology.
29
 In 2006, Austad wrote that “Females do not live longer than males because 
they age slowly, females live longer because they are more robust at every age.”26 He 
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drew this conclusion by dividing the U.S. population into groups by age and comparing 
the rates of death in men and women for all the most frequent causes of mortality. 
It has been hypothesized that chromosomal differences between men and women may 
affect their longevity. After conception in females 1 X chromosome gene is randomly 
inactivated in each cell. X chromosome inactivation typically protects against a double 
dose of X expression in females; however, it also protects females against 
disadvantageous genes on 1 X chromosome. Because women have 2 X chromosomes, a 
female with an abnormal gene on 1 of her X chromosomes can use the normal gene on the 
other and thereby avoid the expression of disease (although she is still a carrier of the 
defect). Men, in contrast, have 1 X chromosome and 1 Y chromosome, and so they cannot 
rely on an alternative chromosome if a gene on 1 of the sex chromosomes is 
defective.
26,31,32
 
Moreover, genetic sex differences are not limited to the nuclear genome. Mitochondria 
are inherited from human mothers only, and, consequently, it has been proposed that the 
mitochondrial genome is optimized for function with the female genome through natural 
selection that predominantly acts on mitochondrial-nuclear genome interactions in 
females.
32
 This optimization of mitochondrial function in cells in females could confer a 
life-span advantage given that mitochondrial dysfunction has been implicated in aging
33
 
and disease.
34,35
 
Experts suspect that gender differences in mortality patterns may be influenced at least in 
part by sex hormones. After conception, different circulating concentrations of sex 
hormones (such as estrogen, progesterone, and testosterone) underlie many of the 
physiological differences between the sexes. Hormonal influences on female biology at 
the organizational level in early fetal and childhood development, as well as after puberty, 
lead to favorable differences in immune function, oxidative stress and antioxidant status, 
lipoprotein metabolism, lipid storage and metabolism, the hypothalamic-pituitary-adrenal 
(HPA) axis stress response, and the ability of cells in females to maintain integrity in the 
face of several stresses. A combination of these factors may play a role in female life 
expectancy advantage.
32
 
In conclusion, in spite of increasing number of studies on aging and longevity, at present 
we still lack strong evidence to support any of the proposed hypotheses. We should also 
consider that all these hypotheses may be not mutually exclusive. Instead, various gender-
related mechanisms may contribute to the gender gap in longevity. 
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1.2.2 Socioeconomic factors 
Throughout the twentieth century, adult mortality rates have exhibited impressive declines 
in all high-income countries. The latter half of the twentieth century was, however, 
characterized by well-documented differences in adult mortality rates across categories of 
socioeconomic status (SES).
36-41
 Many studies show that mortality inequalities related to 
SES tend to be narrower among older age groups,
42-45
 although they persist to 80 years of 
age and older.
42,46-51
 Among the 4 major components of SES (education, occupation, 
income, and wealth), education, often expressed in terms of years of schooling, is 1 of the 
most frequently used when studying socioeconomic differences in adult mortality.
52
 There 
are several reasons for this choice. First, educational attainment is often completed 
relatively early in adult life and usually remains constant throughout adulthood. In 
contrast, occupational status, income level, and the accumulation of wealth may vary in 
considerable ways throughout the life course. For that reason, education may represent a 
proxy for socioeconomic or environmental influences in childhood.
53
 Indeed, education is 
a good indicator of the social backgrounds of children as well as their level of knowledge 
and skills.
54
 Second, because of international similarities in educational systems, use of 
educational attainment as a proxy for SES makes the results of studies from different 
countries easier to compare.
48
 Finally, education typically precedes occupational status, 
income, and the accumulation of the wealth; therefore it may represent a proxy for all 
these factors.  
In all countries studied, death rates are higher in those with less education than those with 
more education. This pattern has been established in comparative works examining 
Scandinavian nations (Denmark, Finland, Norway, and Sweden); western and southern 
countries (Austria, Belgium, Bulgaria, England, France, Italy, Hungary, the Netherlands, 
Spain, and Switzerland); countries in the former Soviet Union (Estonia, Lithuania, and 
Russia); and countries in North America (Canada and the United States).
38,48,50,55-63
 
Socioeconomic inequalities in mortality in old age are likely to be a product of lifetime 
exposures to adverse social and occupational exposures.
64
 Education helps individuals 
acquire resources and attitude that influence health over the life course and, ultimately, 
how and when individuals die. 
Several frameworks have been proposed as possible explanations of socioeconomic 
inequalities in mortality: socioeconomic attainment, health behavior, and psychological 
resources. 
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The association between mortality and educational level might be explained by material 
factors (socioeconomic attainment). Because people with more education tend to have 
higher incomes, they can use the economic resources available to them to pay for better 
life conditions such as nutrition and housing and to live in safer neighborhoods.
52
 A 
longitudinal Dutch study
65
 showed that people with financial problems, adverse income 
situations, or unemployment due to disability have higher mortality after 5 years of 
follow-up than those without such disadvantages. In turn, higher family income is 
associated with lower mortality risk at all ages.
52
 In addition to income, occupational 
status could explain the association between education and mortality. Educated 
individuals are more likely to have regular employment, a high status occupation, and 
more creatively oriented jobs. Studies show that all these factors are associated with better 
health and lower mortality risks.
66-68
 
Other studies show that behavioral factors (health behaviors) partially explain 
socioeconomic inequalities in mortality. There is a well-established increased risk of 
adopting unhealthy lifestyles (smoking, obesity, physical inactivity, and high alcohol 
intake) among people with lower SES.
69,70
 However, Latz et al., 1998,
71
 found that 
lifestyle factors explain no more than 12–13% of the predictive effect of income on 
mortality.  
Finally, researchers suggest that another possible mechanism through which high 
education level improves health and reduces mortality are social psychological resources. 
Highly educated people may have access to other highly educated individuals, who can 
provide help and advice in times of need. For example, Montez et al., 2009,
72
 showed that 
educational differences in mortality are more marked among unmarried than married men. 
It has also been found that lower parental education is significantly associated with 
multiple metabolic risks (i.e., higher insulin, glucose, and cholesterol level) and 
cumulative risk of cardiovascular health problems in adolescence.
73
 
 
1.2.3 Lifestyle factors 
People who live in Sardinia (Italy), Okinawa (Japan), and Loma Linda (California) have a 
significantly longer LE than people in other parts of the developed world. A study of 
people in these areas found that these populations share common lifestyle characteristics 
that may explain their longevity: no smoking; constant moderate physical activity; social 
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engagement; and a diet rich in vegetables, fruits, and whole grains are some of the 
common characteristics.
74
 
Indeed, according to the World Health Organization (WHO), the major causes of death 
among the high-income countries in 2008 were primarily related to lifestyle (Table 1). 
Moreover, several previous studies have reported that longevity and other health-related 
outcomes are associated with healthy lifestyle factors.
75-95
 
 
Table 1 The 10 leading causes of death in high-income countries (2008). Source: WHO 
Causes of death Deaths in millions % of deaths 
Ischemic heart disease 1.42 15.6% 
Stroke and other cerebrovascular disease 0.79 8.7% 
Tracheal, bronchial, and lung cancers 0.54 5.9% 
Alzheimer and other dementias 0.37 4.1% 
Lower respiratory infections 0.35 3.8% 
Chronic obstructive pulmonary disease 0.32 3.5% 
Colon and rectal cancers 0.30 3.3% 
Diabetes mellitus 0.24 2.6% 
Hypertensive heart disease 0.21 2.3% 
Breast cancer 0.17 1.9% 
 
1.2.3.1 Tobacco use 
Tobacco use is a global public-health concern. The use of tobacco is a risk factor for at 
least 6 of the 10 leading cause of death worldwide: ischemic heart disease, 
cerebrovascular disease; tracheal, bronchial, and lung cancers; lower respiratory 
infections; and chronic obstructive pulmonary disease. Worldwide, tobacco use causes 
more than 5 million deaths per year, and current trends show that tobacco use will cause 
more than 8 million deaths annually by 2030.
96
 For every person who dies because of a 
smoking-related disease, 20 more will experience at least 1 serious illness from 
smoking.
97
 The deleterious effects remain even after quitting, although the relative risks 
decline over time. Doll et al., 2004,
98
 compared mortality risk by smoking habits in male 
British doctors in a 50-year follow-up study. They found that smokers died on average 10 
years earlier than non-smokers. Smoking cessation at age 60, 50, 40, and 30 years 
increased life expectancy of approximately 3, 6, 9, and 10 years.  
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Studies on the association between smoking habits and survival in elderly populations 
have yielded inconsistent results. Whereas studies that examined this topic in 60 years and 
older individuals consistently found that smoking predicts higher 
mortality,
81,82,84,88,89,91,94,99,100
 studies on 80 year and older individuals are not consistent. 
In a 2008 study of 6084 city dwellers aged 80 years and older, Dupre et al.,
92
 found that 
current or past smokers were significantly less likely to be among the oldest adults in the 
population. Other studies among nonagenarians
86,101
 and centenarians
87
 have not found a 
significant association between current and/or past smoking habits and longevity. One 
possible explanation is that nonagenarians and centenarians may have genetic or 
environmental characteristics that protect them against the well-known harmful effects of 
tobacco smoking. 
 
1.2.3.2 Body mass index 
The impact of body mass index (BMI) on mortality in the growing elderly population is 
still controversial.
102
 
Obesity is another one leading preventable cause of death worldwide.
103
 In Europe, a 
million deaths (7.7%) each year are attributed to excess weight.
104,105
 On average, obesity 
reduces life expectancy by 6 to 7 years.
106-108
 However, the harmful effects of 
overweight/obesity on survival are weaker in 65 and older than younger adults.
109-111
 A 
review of 13 prospective studies of people aged 65 years and older concluded that 
evidence did not support mild-to-moderate overweight (BMI range from 20 to 27) as a 
risk factor for all-cause mortality.
112
 In addition, only few studies found a significant 
association between BMI over 27 and mortality, this association seems to disappear for 
individuals aged 75 years and older.
112
 The weak association between BMI and mortality 
has been found also in a study on Swedish centenarians.
87
 Furthermore, an inverse 
association between increased BMI and 5-year mortality has been reported among 65 to 
84 year-old male participants in the Finland, Italy, Netherlands Elderly Study (FINE).
85
 
Similar results have been found in Danish nonagenarians, among whom those with a BMI 
greater than 28 had the lowest mortality.
86
 In a more recent review and meta-analysis, 
which included 32 studies, authors concluded that BMI in overweight range is not 
associated with an increased mortality, and that a BMI in the obese range is only 
associated with a modest increase (about 10%) in mortality risk in the elderly.
102
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It is possible that no association between high BMI and mortality has been found among 
individuals aged 75 years and older because those who were obese (BMI 30 or higher) 
may already have died. It has been suggested that the positive association between 
increased BMI in elderly people and survival is caused by fat stores that are different to 
and metabolically better than fat stores in young adults.
113
 Indeed, there is evidence that 
the type and distribution of fat stores in older people differs from those in young 
adults.
114,115
 
A number of studies have reported increased mortality among individuals in the lowest 
BMI categories.
102,108,110,112,116,117
 The mortality rate tends to increase when BMI falls 
below the range of 19–23. Being underweight was found to be associated whit loss of 
peripheral and respiratory muscles
118
 and it might increase vulnerability to acute 
disease,
119
 this might explain the association between underweight and increased 
mortality. Moreover the reverse causation is a concern in studies of lower BMI and 
mortality, the possibility that pre-existing illnesses or condition associated with increased 
mortality lead to loss of body weight.
102
 
 
1.2.3.3 Alcohol consumption  
Together with tobacco, smoking, and obesity, over-consumption of alcohol is listed 
among the leading preventable causes of death worldwide.
103
 Several studies have found a 
U- or J-shape association between alcohol intake and mortality. Heavy drinkers but also 
abstainers have higher mortality than light and moderate drinkers.
120-125
 In a recent report, 
researchers found that light wine consumption was associated with a 5-year increase in 
life expectancy.
126
 
In older people, however, the relationship between alcohol consumption and mortality is 
not so clear.
127
 Four studies among elderly people have reported an increased mortality 
risk associated with increased alcohol intake.
81,125,128,129
An average weekly consumption 
of 14 or more drinks gave older men—but not older women—a higher risk of mortality 
than non-drinkers of the same age.
128
 Doll et al, 1994,
129
 reported that male doctors who 
consumed 29 or more drinks a week had a higher risk of mortality than male doctors who 
did not drink. A U-shape relationship has been found between alcohol consumption and 
mortality risk in elderly Danes. Abstainers and heavy drinkers (28 drinks or more a week 
for women, 69 drinks or more a week for men) had a higher risk of dying than light 
drinkers.
125
 Finally, mortality risk was found to be 2 times higher among elderly people 
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who consumed more than 14 drinks per week than among abstainers.
81
 In contrast, 4 
studies have reported an inverse association between mortality and increased alcohol 
intake in older people.
82,99,130,131
 People aged 60–79 years in the United States who 
reported a weekly consumption of 28 drinks or more were found to have a lower risk of 
mortality than nondrinkers.
130
 Elderly Australian men, but not women, who had this same 
level of alcohol consumption, had survived longer than non-drinkers.
99
 A study of an 
elderly Mediterranean population found that those who drank moderately or heavily had a 
lower risk of mortality than nondrinkers.
82
 Finally, McCaul et al., 2010,
131
 investigated 
the effect of alcohol intake on 10-year mortality in men and women over the age of 65. 
They found that the risk of all-cause mortality was lower in men who consumed up to 4 
standard drinks per day and in women who consumed 1 or 2 standard drinks per day than 
in older adults of the same sex who did not consume alcohol every week. Other studies 
have not found any association between alcohol intake and mortality.
84,86,94,101,121,122,132-139
 
Possible explanations for the inconsistent findings from these studies are the variation in 
the study-specific cut-points, the choice of the reference group, and likely classification 
errors. Underreporting of alcohol use could also have prevented the detection of adverse 
effects. Finally, the survival cohort effect should be also taken into account. People with 
alcohol-related diseases could die prematurely, leaving a cohort that is less susceptible to 
the adverse effects of alcohol. Many biological changes should make elderly people more 
vulnerable to excessive alcohol consumption than adult population. Moreover, elderly 
people are more likely than younger people to have multiple comorbidities
14
 and to use 
more medication.
127
 Alcohol may interact differently with different chronic diseases and 
with medication to adversely affect health outcomes. Thus, caution is necessary in the 
interpretation of the inverse association between heavy alcohol intake and mortality.  
 
1.2.3.4 Social network 
The influence of social relations on mortality is well documented. A recent meta-analysis 
of 148 studies confirms that social relationships significantly predict mortality.
140
 
However, it is unclear if all social relationships are equally beneficial to elderly people or 
if specific types of relationships are more advantageous. Giles et al., 2005,
141
 showed that 
the beneficial association between social networks and survival may be restricted to 
relationships with friends and confidents rather than with children and relatives. In a 
meta-analysis of 53 prospective observational studies of elderly people, marriage or 
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support from a partner was found be a significant independent predictor of survival; the 
overall reduction in mortality risk was 9–15%. However, this association was statistically 
significant in only half the studies.
142
 
Social integration may influence survival via several potential mechanisms. For instance, 
social integration may influence health behaviors.
143-145
 It has been demonstrated, for 
example, that social integration is significantly associated with physical activity.
146
 Social 
relationships may provide resources for adaptive behavioral or neuroendocrine responses 
to acute or chronic stressors. Although it has been found that physiological activation in 
response to stressors is beneficial up to a point, excessive activation may have hidden 
costs.
147
 Supportive social relationships can moderate stress responses indirectly; for 
example through practical assistance in time of need.
148
 
 
1.2.3.5 Physical and leisure-time activity 
The majority of the studies that investigate the relationship between leisure activities and 
health focus mainly on younger or middle-age populations; few reports have examined 
the association between these factors and survival among elderly people. However, a 
growing body of empirical evidence suggests that being active and participating in 
different kinds of leisure activities has a positive effect on survival, even among elderly 
people. 
Physical activity (PA). The connection between PA and mortality has been well studied. 
Three recent systematic reviews and meta-analyses of observational studies have shown 
that PA reduces mortality among men and women.
149-151
 However, as most of the studies 
included in these reviews involved people who were 20 and 65 years old, it is unclear 
whether these results are generalizable to older people. A recent study of 14000 elderly 
people followed for 28 years showed that any amount of time spent in PA resulted in a 
lower risk of mortality. This effect was reached even with a level of PA lower than the 
current guidelines for older people: a minimum of 30 minutes of moderately intensive 
activity 5 days a week.
152
 A population-based cohort study of 2357 men aged 65 and older 
suggests that regular rigorous exercise decreases mortality risk.
94
 Parallel results have 
been found in the 2600 participants aged 75 years and older enrolled in the Survey in 
Europe on Nutrition and the Elderly; a Concerted Action (SENECA)
89
 and in participants 
in the Italian Silver Network Home Care Project (2757 people 70 years of age and older 
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who were followed for at least 1 year).
153
 Comparison between these studies is not easy 
because various definitions of PA and activity levels were used.  
Leisure-time activity. Far fewer studies have analyzed the association between activities 
that have a physical component and mortality in elderly adults. In a study of 2761 
American men and women aged 65 and older, researchers found that increased 
participation in social activities (such as attending church; going to the movies, to the 
theater, or to sporting events; and playing games) and productive activities (such as 
gardening, shopping, community work, and cooking) was associated with decreased 
mortality.
154
 In a Swedish cohort of 463 people aged 77 and older, greater participation in 
solitary activities with a physical component (gardening and other hobbies) was 
associated with a significant reduction in mortality.
155
 In a 6-year follow-up analysis of 
2291 people aged 67 to 95 years, a greater overall activity level was associated with 
reduced mortality. Activities were classified as follows: social activities (visiting family 
and friends, church-related activities, and sports); solitary activities (hobbies, going to the 
theater, music, art, reading, and writing); and productive activities (volunteer work, 
housework, gardening, and yard work).
156
 In the Leisure World Cohort Study, 14000 
elderly men and women (median age 74 years) were followed for 28 years, and different 
activities were analyzed in relation to survival. Participation in less physically demanding 
activities reduced mortality, as did participation in physical activities.
157
 These results 
were confirmed in a Swedish cohort of 1246 people (mean age 75 years).
158
 Engagement 
in hobbies, dancing, organizational activities, and gardening were found to be associated 
with reduced mortality. 
 
Various pathways between leisure activity and survival have been suggested. Physical 
activity may effect mortality risk through physiological pathways, such as improving 
cardiovascular health
159
 and functional status.
160
 Psychosocial pathway may be involved 
in the health benefits of activity. Social participation often provides individuals with 
meaningful roles, greater social networks, and social support, which protect against 
damaging physiological responses by improving coping abilities and heath behaviors.
161
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1.2.4 Genetic factors 
The genetic contribution to longevity and human aging is likely to result from many 
different genes, each of which makes a modest contribution.
162
 Some genes likely affect 
longevity by increasing predisposition to age-related diseases and early death; other genes 
are likely to slow the aging process itself, leading to a longer life. We still do not know, 
however, how genetic factors interact with modifiable behavioral and environmental 
factors to contribute to longevity.
162
 
The genetic contribution to longevity has been estimated using twin studies as well as 
population based studies (Table 2). Most heritability estimates from twin registers range 
between 20 and 30%,
24,163,164
 whereas estimates from population-based studies are 
slightly lower, ranging from 15 to 25%.
165-167
 Evidence shows that genetic influences on 
longevity may vary by ethnicity.
168
 One study shows that African Americans have a 
lower heritability than European or Caribbean Hispanic populations.
168
 In 2006, 
Hjelmborg et al.,
169
 published the results of a study on the genetic influence on human 
lifespan and how it varies across age, using Nordic twin cohorts (Danish, Finnish, and 
Swedish). They reported that the genetic effect on lifespan is minimal before age 60 
years, but increases thereafter.  
 
Table 2 Estimates of heritability contribution to longevity from different studies 
Sample Heritability 
Danish twins
24,163
 20–30% 
Swedish twins
164
 33% 
Old Order Amish population
165
 25% 
Utah Population Database
166
 15% 
Framingham Heart Study
167
 16% 
Medicare recipients, New York City
168
  
European ancestry 26% 
African American 4% 
Caribbean Hispanic 29% 
 
To identify genes that influence human longevity, both linkage and association studies 
have been carried out. Linkage analysis is used to map genetic loci and is based on 
observations of closely related individuals.
170
 These kind of analyses often have the 
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disadvantage of a lack of availability of multi-generational DNA from long-lived 
individuals and the complexity of increased lifespan as a trait.
171
 
Association studies investigate the relationships of specific variants of candidate genetic 
with a given phenotype. One type of study design often applied in association studies is 
the case-control design. These studies are designed to compare frequencies of variation in 
candidate genes between groups. A proper control group is critical in these studies to 
avoid the introduction of severe bias. Longitudinal studies, in which a cohort of 
individuals is followed over time, make it possible to examine incident events in relation 
to specific genetic variations. So far, in most studies on the effect of genetic variations on 
longevity, researchers have examined only 1 or at most a few SNPs in the same genes. 
These variations are often chosen for their possible effect on protein function or level of 
expression. However, haplotype analyses or “whole gene” analyses, undertaken by 
tagging SNPs, might increase the possibility of finding an association between variation 
in genes and longevity. To date, 7 genome-wide association studies (GWAS) on longevity 
have been performed.
172-178
 Genome-wide association studies can be problematic, 
however, because the massive number of statistical tests performed presents an 
unprecedented potential for false-positive results.
179
 
Using all these approaches, many candidate genes have been investigated in relation to 
survival or longevity. As yet, however, only a few genetic variants have been found to 
influence longevity. Apolipoprotein E (APOE) is the only gene with common variants 
that have consistently reported associations with longevity in humans, supposedly via 
their association with both Alzheimer’s and cardiovascular disease.171 Many initially 
positive findings between other candidate genes and longevity have not been replicated. 
Some of the most thoroughly investigated or biologically most plausible candidate genes 
are listed in Table 3. 
The discrepancy in the findings of the different studies might be the result of differences 
in experimental design, sample size, criteria used in selecting subjects, and examination of 
different alleles in the same gene. In addition, the association between polymorphisms 
and mortality might have a population-specific component; it may be affected by the 
population-specific gene pool, gene-environmental interactions, or both. Absence of a 
statistically significant association does not necessarily mean that there is no association; 
thus, it is important to continue these studies in larger cohorts to increase our 
understanding of mechanisms that contribute to increased survival. 
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In summary the scientific world has shown an increased interest in the aging phenotype, 
probably as a consequence of the increasing average human lifespan and the growing 
percentage of elderly people in the population. This thesis attempted to investigate only 
some of the potential determinants of longevity. In addition to the numerous factors 
discussed here, others important factors contribute to the human longevity. These include 
but may not be limited to psychological problems (stress), violent deaths (suicide, 
homicide, and motor vehicle accidents), and the environment and occupation exposure 
(air pollution, ultraviolet light, toxic metals/solvents, and food and water supply). 
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Table 3 Selected human candidate genes involved in survival 
Gene names (symbol) Protein function Pathway Study design Population, reference 
    Positive association  No association 
Angiotensin I-
Converting Enzyme 
(ACE) 
Hydrolyses angiotensin I 
to angiotensin II 
Risk factor for 
cardiovascular 
diseases 
Case-control  Brazilian (European origin),
180
 
Chinese,
181
 Columbian,
182
 Croatian 
and European,
183
 English,
184 
French,
185,186 
German,
187
 Italian,
188
 
Russian
189
 
American Caucasians,
190
 
Chinese,
191
 Danish,
192-194
 
Dutch,
195
 European,
196
 
French,
197
 Italian,
198
 Korean,
199
 
Polish,
200
 Spanish
201
 
 
 
 Longitudinal  Chinese,
202
 Danish,
203
 Dutch
204
  
Apolipoprotein A 
(APOA) 
Promotes cholesterol 
efflux from tissues to the 
liver for excretion 
Risk factor for 
cardiovascular 
diseases 
Case-control  Italian
205,206
 French
207
 
 
 
 Longitudinal  Danish
208
  
Apolipoprotein C 
(APOC) 
Component of very low 
density lipoproteins and 
chylomicrons 
Risk factor for 
cardiovascular 
diseases 
Case-control  English,
184
 Finnish,
209
 Jerusalem,
210
 
Russian
211
 
 
   GWAS study  German
178
  
Apolipoprotein E 
(APOE) 
 
Ligand for the LDL 
receptor – transportation 
of cholesterol 
Risk factor for 
cardiovascular 
and 
Alzheimer’s 
disease.            
Stress response 
Case-control  Chinese,
212,213
 European,
214
 
Finnish,
209,215,216
 French,
185,197
 
Greek,
217
 Italian,
188,218
 Jerusalem,
219
  
Swedish
220
 
Brazilian,
221
 Columbian,
182
 
English,
184
 Italian,
222
 
Japanase,
223
 Korean
199
 
  Longitudinal American (Utah),
224
 Danish,
225,226
 
Finnish
227
 Swedish
228
 
Finnish
229,230
                       
Dutch
231
 
  GWAS study Dutch
177
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Gene names (symbol) Protein function Pathway Study design Population, reference 
    Positive association  No association 
Insulin-like growth 
factor 1 receptor 
(IGF1R) 
The receptor of the 
insulin-like growth factor 
– stimulator of cell 
growth 
Stress response Case-control  Italian,
232
 Jerusalem
233
  
Interleukin 6 (IL-6) An immune regulatory 
cytokin–acute phase 
response; e.g., fever 
Inflammation 
and stress 
response  
Case-control Danish,
234
 Finnish,
235
 Italian,
236
 
Irish
237
 
Bulgarian,
238
 Finnish,
239
 
Irish,
240
 
Italian,
241,242
Japanese
243
 
   Longitudinal Italian
244
 American
245
 
Interleukin 10 (IL-10) Anti-inflammatory 
cytokine 
Inflammation, 
and stress 
response 
Case-control Finnish,
239
 Italian,
246,247
 Japanese,
243
 
Jordanian
248
 
Bulgarian,
238
 Irish,
240
 Italian
241
 
Tyrosine hydroxylase 
(TH) 
Enzyme responsible for 
catalyzing the conversion 
of the amino acid L-
tyrosine to L-3,4-
dihydroxyphenylalanine 
Stress response Case-control Italian
249,250
 German
251
 
Paraoxonase 1 
(PON1) 
Preserves high-density 
lipoprotein function and 
protects low-density 
lipoprotein from 
oxidative modification  
Stress response 
and neuro-
degenerative 
diseases 
Case-control French,
252
 Italian,
253-255
,           
Various (meta-analysis)
256
 
Danish,
257
 Irish,
255
          
Various (meta-analysis)
258
 
   GWAS  Various (meta-analysis)
175
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2 AIMS 
2.1 GENERAL AIMS  
The overall aim of this thesis is to detect the most relevant factors that lead to longer 
survival after age 75. The thesis will explore the role of health, lifestyle, social 
environment, and genetic background in the probability of reaching a very advanced age. 
The major research questions are: What is the impact of the most common chronic 
diseases in the elderly people on their survival? What effects do lifestyles and social 
environment have on life span? Does the most important component of longevity lie in 
our genes?  
 
2.2 SPECIFIC AIMS 
The following specific aims are addressed in the 4 studies included in this thesis:  
1. To investigate the impact of major age-related diseases (such as dementia, cancer, 
and cardiovascular diseases) on survival time. We hypothesized that type and 
duration of disease have different impacts on survival (Study I). 
2. To explore the influence of the apolipoprotein E (APOE) gene on mortality in old 
age. We addressed this aim by testing the following hypotheses: 1) APOE ε2- and ε4-
allele have different associations with survival; and 2) the association between allelic-
variation in APOE and survival is probably mediated by dementia and ischemic heart 
and cerebrovascular disease (IHCD) (Study II). 
3. To examine the associations between various modifiable factors with length of life, 
taking in account social background and medical conditions such as chronic diseases 
and multimorbidity. We hypothesize that: 1) lifestyle behaviors predict survival after 
age 75 and even among the oldest old (85 years and older); 2) combinations of 
different modifiable factors have different associations with survival (Study III). 
4. To detect the combined effect of lifestyle and genetic factors on lifespan by exploring 
2 hypotheses: 1) allelic-variation in genes might have a certain influence on survival 
and 2) longevity may result from a complex relationship between genetic and 
lifestyle factors (Study IV). 
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3 METHODS  
The data in this thesis are gathered from the Kungsholmen Project. 
 
3.1 THE KUNGSHOLMEN PROJECT 
3.1.1 Study population 
The Kungsholmen Project is a community-based longitudinal study on aging and 
dementia that was launched in 1987. The initial population included all registered 
inhabitants (n=2368) who were living in the Kungsholmen district of Stockholm and 
were aged 75 years and older.
259,260
 Of these, 76.4% agree to participate in the project 
(n=1810). The baseline survey (1987–1989) included screening phase with a brief 
cognitive test (mini-mental state examination – MMSE) for all participants followed by 
a clinical phase for persons with cognitive impairment (MMSE≤23) and a random 
sample of those without impairment (MMSE>23). Five follow-ups at approximately 3-
year intervals were completed before termination of data collection in 2000.  
The baseline population in the Kungsholmen Project and the participants in the 4 studies 
included in this thesis are described in Figure 8.  
 
 
Figure 8 Kungsholmen project’s baseline study population and participants in 
the 4 studies 
 
 
 
 
 
 
 
 
 
 
 
2368 aged 75 years and older                                                                
living in the Kungsholmen area of Stockholm 
110 dropouts 
471 no DNA 
 
1810 
Screened subjects 
Participants 
Study III 
Participants 
Study I 
Participants 
Study II 
Participants 
Study IV 
1307 
1094 
1229 
110 dropouts 
471 no DNA 
132 never re-evaluated 
3     ɛ2ɛ2 allele 
110 dropouts 
225 prevalent dementia cases 
168 never re-evaluated 
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3.1.2 Data collection 
At each follow-up, physicians clinically examined all participants according to a 
standard protocol, trained personnel administered psychological tests, and nurses 
collected data on family and personal history.
259,260
 If the parcticipant was not able to 
answer, an informant, usually a next-of-kin was interviewed.  
Socioeconomic status (SES) assessment. SES was evaluated using 2 different variables: 
education and occupation. Education level was measured as total years of formal 
schooling. The variable was further divided into 3 main categories: primary (6 years of 
primary school and, in some cases, 1 year of practical vocational training); secondary 
(8–12 years), and university level (13+ years). All analyses were performed using the 3 
educational levels; however, as results in the last 2 groups were comparable, we 
reported only findings related to primary versus secondary/university levels. 
Occupation-based SES was assessed at first follow-up by trained nurses who 
interviewed the participants or a relative about the lifetime work history of each 
participant. The interview questionnaire was developed by an expert in occupational 
medicine and explored lifetime work activities. Information collected about lifetime 
work activities included employer, job title, period of employment, and tasks for all jobs 
lasting at least 6 months.
261
 All occupational periods were grouped according to the 
Swedish socioeconomic classification system (SEI) developed by Statistics Sweden 
(1982).
262
 The longest job held during the lifetime was used to categorize people as 
blue-collar workers (low occupation-based SES), white-collar employees (intermediate 
occupation-based SES), and self-employed and academic professionals (high 
occupation-based SES). The last 2 groups were merged in all analyses. 
Life habits assessment. Information on smoking and alcohol consumption was obtained 
from baseline data or, if information was missing at baseline, from data collected at the 
first follow-up, 3 years after baseline. Smoking history was assessed by asking 
participants whether they had ever smoked. Smokers and former smokers were asked 
how long they had smoked and the number of cigarettes smoked per day. Former 
smokers were also asked at what age they had stopped smoking. We categorized 
smoking status as current, former, and never.
263
 
Data on alcohol consumption were collected using a standard questionnaire, including 
whether the subject drank wine, beer, or liquor, and the frequency (never or 
occasionally, monthly, weekly, or daily) and the quantity of alcohol drinking. The 
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average daily absolute alcohol intake was estimated using the frequency and quantity of 
consumption. Ethanol (pure alcohol) content was estimated to be 13.2 g for a bottle or 
can of beer [12-ounce (340.8 cc) bottle or can], 10.8 g for a standard glass of wine, and 
15.1 g for a drink (counting a drink as 44 ml) of liquor.
264
 The total ethanol intake for 
each participant was computed as the sum of contributions from beer, wine, and liquor. 
The total intake of ethanol was converted into standard units (1 unit = 8 g ethanol) per 
week for each participant on the basis of the recommendations made by the Royal 
College of Physicians, Psychiatrists, and General Practitioners.
265,266
 All participants 
were then divided into 4 categories by units of ethanol intake: those who never drank; 
occasional drinkers (<1 unit per week), light to moderate drinkers (1–21 units per week 
for men, or 1–14 units per week for women), and heavy drinkers (>21 units per week 
for men, or >14 units per week for women).
267
 At baseline only 6% of the participants 
reported being heavy drinkers. In our analyses, alcohol consumption was categorized as 
yes (light/moderate and heavy drinkers) or no (those who never drank and occasional 
drinkers).  
BMI was considered an indicator of life habits because of its close association with food 
intake and physical activities. BMI was computed as the ratio of weight in kilograms to 
the square of height in meters (weight/(height)
2
), using direct measurements, and we 
used widely used cut-offs to categorize the participants as overweight (BMI >25), of 
normal weight (20–25), or underweight (<20).268 
A life-habit variable was created based only on smoking and BMI. Alcohol was not 
included because of the high percent of missing values (32%). The life-habit variable was 
coded as unhealthy (were overweight/underweight and were current/former smokers), 
moderately healthy (were overweight/underweight or were current/former smokers) and 
healthy (were normal-weight and had never smoked). 
Leisure activity assessment. Participants were asked whether they regularly engaged in 
any particular activities or belonged to any organizations. If they answered yes, they were 
asked to specify the types of activities or organizations and to report the frequency of 
participation. We grouped the reported activities into mental, physical, social, and 
productive on the basis of the classification used in previous studies.
269
 The frequency of 
participation in any leisure activity was initially recorded as daily, weekly, monthly, or 
annually. On the basis of the answers, we categorized the frequency as no participation, 
daily to weekly participation, and monthly participation. Owing to the statistical power of 
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the study, we analyzed survival in relation to participation in each type of activity (at least 
monthly) compared with no participation. Participants were assigned to a particular group 
if they participated in at least 1 of that group’s activities. Mental activities included 
reading books or newspapers, writing, studying, doing crossword puzzles, painting, or 
drawing. Physical activities encompassed swimming, walking, or gymnastics. Social 
activities consisted of attending the theatre, concerts, or art exhibitions; traveling; playing 
cards or games; or participating in social groups or an organization for older people. 
Productive activities included gardening; housekeeping; cooking; working for pay after 
retirement; doing volunteer work; and sewing, knitting, crocheting, or weaving. 
Social network assessment. To determine the extent of social networks, we asked 
participants about marital status, living arrangements, parenthood, and friendships. We 
also asked about frequency of contact with children and friends or relatives and how 
satisfied participants were with the frequency of those contacts. On the basis of their 
answers, we grouped the participants into the 3 social network categories: rich, moderate, 
and limited or poor.
270
 The group with a rich social network included those who were 
married and lived with someone, had children with whom they were in daily to weekly 
contact and who found this level of contact satisfactory, and had relatives or friends with 
whom they were in daily to weekly contact and found this level of contact satisfactory. 
The group with a moderate social network included those who had any 2 of the 3 
elements. The group with a limited or poor social network included those who had 1 or 
none of the 3 elements. 
Risk profile groups. Four different risk profile groups were created on the basis of life 
habits, participation in leisure activities, and participants’ social networks. The risk profile 
groups are shown in Table 4.  
We used the participants with high risk profile as the reference group. This group 
included all participants who had unhealthy life habits, a limited or poor social network, 
and did not engage in any leisure activities. The other 3 risk profile groups were: those 
with a moderately high risk profile, those with a moderately low risk profile, and those 
with a low risk profile. The moderately high risk profile included those participants with 
at least 2 of the 3 risk factors. The moderately low risk profile included those with only 1 
of the 3 risk factors, and the low risk profile included those who had healthy life habits, 
had a rich or moderate social network, and engaged in at least 1 leisure activity. 
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Table 4 The 4 risk profile groups include the high risk profile (dark gray), the moderately 
high risk profile (light grey), the moderately low risk profile (very light gray), and the low 
risk profile (white) 
Life habits Leisure 
activities 
Social network 
Moderate or rich Limited or poor 
H
e
a
lt
h
y
 
At least one LOW Moderately LOW 
None Moderately LOW Moderately HIGH 
U
n
h
e
a
lt
h
y
 
At least one Moderately LOW Moderately HIGH 
None Moderately HIGH HIGH 
 
Assessment of chronic diseases and multimorbidity. A disease was classified as chronic if 
1 or more of the following characteristics were present: 1) the disease was permanent, 2) 
it was caused by non-reversible pathological alteration, 3) it required rehabilitation, or 4) 
it required a long period of care.
271
 Chronic disorders were diagnosed by the examining 
physician on the basis of clinical examination, medical history, laboratory data, and 
current use of medications. The participants were asked by physicians to show 
prescription forms and/or the containers of the drugs they used. Drugs were classified on 
the basis of to the Anatomical Therapeutic Chemical (ATC) classification system.
272
 
Diagnoses of diseases were also derived from the computerized Stockholm inpatient 
register system for the years 1969 to 1998. The registry allowed us to identify subjects 
who already had the specific chronic disease at baseline (prevalent cases), as well as 
incident cases at follow-up. The International Classification of Diseases, Eighth and Ninth 
revisions (ICD-8 and 9) were used for all diagnoses in the inpatient register system, 
except for sensory function disorders, anemia, the various types of dementia, and major 
depression.  
With regard to sensory function, deafness was defined the inability to hear the 
interviewer’s voice, and visual impairment was defined as being blind or almost blind. 
Anemia was defined as hemoglobin<13 g/dl in men and <12 g/dl in women.
273
 Dementia, 
various types of dementia, and major depression were diagnosed by a psychiatrist on the 
basis of the criteria in the Diagnostic and Statistical Manual of Mental Disorders, Revised 
Third Edition (DSM-III-R).
274-276
All preliminary diagnoses of dementia were reviewed by 
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a senior specialist, and a third opinion was solicited in case of disagreement.
259
 For the 
persons who died before the follow-up examination, dementia was diagnosed 
retrospectively using information in hospital records and death certificates. Medical 
records and death certificates were available for all persons who died during the follow-up 
periods. Dementia types were classified as follows: Alzheimer’s disease (AD); vascular 
dementia (VaD), which also included mixed dementia; and other dementia (OD), which 
included alcoholic dementia, dementia in Parkinson’s disease, and unspecified cases of 
dementia. Cases diagnosed as questionable dementia have been excluded from these 
analyses. Age at onset of the disease was defined as the middle point between the last 
follow-up without the disease and the first follow-up with the disease. 
Thirty-eight chronic conditions were selected, of which had a prevalence greater than 
0.4% in the Kungsholmen Project study population. These 38 chronic conditions were 
coded as 0 (condition absent) and 1 (condition present). A summary chronic condition 
variable was created by counting of the number of diseases and categorizing the sum into 
3 groups: no conditions, 1 condition, and 2 or more conditions. Multimorbidity was 
defined as the co-occurrence of 2 or more chronic conditions in the same individual, 
whether coincidental or not.
14
 
The variable ischemic heart and cerebrovascular diseases (IHCD) was defined as the 
presence of the following diseases, classified according to the ICD-8 and 9: ischemic 
heart disease (410-414) or cerebrovascular disease (430-438). This variable included all 
the diseases with a documented association with APOE.  
Genotyping procedure. A total of 1229 DNA samples from Kungsholmen Project 
participants were analyzed using matrix-assisted laser desorption/ionization time-of-flight 
mass spectrometry (MALDI-TOF), which differentiates genotypes on the basis of the 
mass of variant DNA sequences. The method is based on polymerase chain reaction 
(PCR), which uses an extension primer adjacent to the polymorphic site. In the PCR, 
allele-specific products are generated that have unique molecular mass and can be 
distinguished using mass spectrometry. iPLEX™ (Increased Plexing Efficiency and 
Flexibility for MassARRAY
®
) chemistry was used. The procedure was performed on the 
Massarray Analyzer platform from SEQUENOM
®
. The following genes were analyzed: 
angiotensin I-converting enzyme (ACE, rs4343 and rs1800764), apolipoprotein B (APOB, 
rs693), 3-hydroxy-3-methylglutaryl-CoA reductase (HMG-CoA reductase, rs3761740), 
methylenetetrahydrofolate reductase (MTHFR, rs1801133), apolipoprotein C-1 (APOC1, 
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rs4420638), lipoprotein lipase (LPL, rs328), lipase (LIPC, rs1800588), the fat mass and 
obesity associated gene (FTO, rs9939609), brain-derived neurotrophic factor (BDNF, 
rs6265), apolipoprotein E (APOE), insulin-degrading enzyme (IDE, rs1887922 and 
rs1544210), insulin-like growth factor 1 (IGF1, rs2229765), phosphatidylinositol 3-
kinases (PI3K, rs361072), and interleukin 6 (IL-6, rs1800795). 
Vital status assessment. Information about the vital status of the participants was derived 
from the official mortality data provided by Statistics Sweden. Information was available 
until 2003 for the Study I, 2005 for the Studies II and III, and until 2008 for Study IV. 
 
3.2 STATISTICAL ANALYSIS 
A range of statistical analyses were used in the 4 studies. To present baseline 
characteristics of the cohort, univariable analyses were performed with Chi-square test for 
categorical data and Student’s t-test for continuous data. The Hardy Weinberg equilibrium 
in the population was tested for all genotypes. 
The main outcome of interest was the time elapsed from date of birth to date of death, if it 
occurred during the study period. The measures used to summarize and compare the 
distribution of the outcome across exposure levels were mortality rates or median time to 
death. The regression models associated with those measures were the Cox regression for 
mortality rates and Laplace regression for median survival. 
In multivariable Cox regression models, age was used as time-scale to better adjust for 
potential confounding by age.
277
 The proportional hazard assumption was verified by 
regressing the Scaled Schoenfeld’s residuals against survival time.277,278 If any indication 
of no proportionality was detected, the plot of the residuals along with a smoother was 
studied to determine whether the mean residual varied as a function of time. If that was 
the case, a time-varying covariate was introduced in the model.  
Empirical survival curves were produced using the Kaplan-Meier estimator of age-
specific proportions of surviving individuals. A log-rank test was used to compare the 
statistical significance of survival curves.  
We examined potential statistical interactions between covariates, including the 
independent variables and their cross-product terms in the same model. We formally 
tested for statistical interaction using the likelihood ratio test.  
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In Studies I and II, all diseases were modeled as time-dependent covariates to take into 
account the possible change over time of the diseases status (i.e. from not-affected to 
affected by the disease). 
Laplace regression is a statistical model that makes inferences on percentiles (i.e. median) 
of survival time conditionally on covariates, while taking into account the presence of 
censored observations. In the absence of covariates, Laplace regression provides estimates 
of survival percentiles similar to the non-parametric Kaplan-Meier method. However, 
unlike Kaplan-Meier analysis, Laplace regression allows researchers to model the 
association between continuous exposures, adjusting for confounders, and to assess 
interactions in predicting survival time.
279,280
 
Statistical analyses for all studies were performed and graphs created with Stata
®
, version 
9.2 or later (StataCorp, TX, USA).   
Table 5 summarizes the outcomes, exposures, potential confounders, and statistical 
analyses that were used in the 4 studies. 
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Table 5 Outcome, exposures, potential cofounders, and statistical analyses used in the studies included in this thesis 
Study Outcome  Exposures Potential confounders Statistical analyses Comments 
Study I Mortality during 16 
years of follow-up 
Dementia, CVD, and cancer                
Dementia subtypes 
Gender, education, 
prevalent cases of 
CVD, and cancer 
Cox model, using age as time-scale First model: sex- and education  
Second model: sex, education, and 
prevalent cases of CVD and cancer 
 Mean survival time Dementia, CVD, and cancer                
Dementia severity  
Actual years from diagnosis to death  
 Potential years of 
life lost 
Dementia, CVD, and cancer              Age-specific mortality was multiplied 
by age-specific life expectancy 
based on the life-table analysis 
 
Study II Mortality during 18 
years of follow-up 
APOE  Gender, education, 
dementia, and IHCD 
Cox model, using age as time-scale First model: sex and education  
Second model: sex, education, and/or 
dementia/cancer 
Third model: all the previous models were 
reported stratifying by sex 
 Years of life lost or 
gained 
APOE  Comparing the mean value of age at 
death 
 
Study III Median age at death 
during 18 years of 
follow-up 
Lifestyle factors, leisure 
activities, and social network 
Combination of various 
patterns of modifiable factors 
Age, gender, education, 
SES, morbidity, and 
multimorbidity 
Laplace model First model: age 
Second model: Age, gender, education, 
SES, morbidity, and multimorbidity 
Stratified by sex, age, or number of chronic 
conditions 
Study IV Mortality during 20 
years of follow-up 
Genetic factors          
Specific profiles of genetic 
and lifestyle factors 
Gender  
 
Cox model, using age as time-scale 
 
Model: gender 
 
 Median age at death Specific profiles of genetic 
and lifestyle factors 
Age and gender Laplace model  Model: age and gender 
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3.2.1 Imputation of missing data 
Missing values are inevitable in epidemiological studies. The problem of analyzing 
incompletely observed data has been extensively studied in statistical literature.
281-283
 
The proportion of missing covariate data in the different studies ranged from 4% for 
leisure activities to 32% for alcohol consumption. The simple deletion of cases with any 
missing values would results in discarding up to 40% of the participants. A complete case 
analysis, discarding observations with incomplete information, is the standard way a 
statistical software deals with missing data. Concerns include loss of efficiency and 
possible bias when systematic differences between observed and unobserved values are 
related to a specific exposure-disease association.
284
 
Multiple imputation techniques have been proposed as a valid alternative and are 
increasingly implemented in statistical software packages. We used a method of multiple 
multivariate imputations of missing values that has been developed for Stata, the 
multivariate imputation by chained equations (MICE).
283
 
In the imputation model for each variable with missing values we included several 
predictors (i.e. age, gender, educational level, survival time, and outcome status). The 
specification of a proper imputation model makes more realistic the so-called “missing at 
random (MAR)” assumption. The assumption is that missingness is just due to chance 
once taking into account (conditioning on) all the predictors included in the imputation 
model.
285
 
The results obtained from multivariable regression models estimated on the basis of 50 
imputed datasets were then combined using Rubin’s rule to produce overall estimates and 
standard errors that reflect missing-data uncertainty.
286
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4 ETHICAL CONSIDERATIONS 
Informed consent was obtained at baseline from the Kungsholmen Project study 
participants, after explaining the aims of the project and clarifying that all information 
would be kept strictly confidential. If there was any indication that the participant had 
severe cognitive impairment, consent was obtained from a proxy, usually a next-of-kin or 
close relative. However, the examination or interview was interrupted if the participant 
expressed anguish or discomfort in any way, regardless of whether informed consent had 
been given by the participants themselves or by a proxy. All phases of the Kungsholmen 
Project were approved by the Ethics Committee at Karolinska Institutet, Stockholm, 
Sweden. 
Studies I and II included in this thesis used the data collected from Phase I to Phase V of 
the Kungsholmen Project, data from medical records, and information from the Inpatient 
register database. Studies III and IV used the data collected during the baseline survey 
(Phases I & II) of the Kungsholmen Project. All 4 studies used data from death 
certificates.  
For each phase of data collection, approval from the Ethics Committee at the Karolinska 
Institutet was obtained: 
 Phases I & II (baseline survey): Dnr. 87:148; Dnr. 87:234 
 Phase III (the first follow-up examination): Dnr. 90:251 
 Phase IV(the second follow-up evaluation): Dnr. 94:122 
 Phase V (the third follow-up examination): Dnr. 99:308 
 Death certificate and Inpatient register data: Dnr. 99:025; Dnr. 01:020 
 
All staff working with the Kungsholmen Project database follow the guidelines of the 
Swedish Council for Research in the Humanities and Social Sciences: the principles of 
autonomy and integrity, the rule of consent, and the demand for research.
287
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5 RESULTS 
In this section of the thesis, the main results from studies I to IV are presented.  
 
5.1 AGE-RELATED CHRONIC DISEASES AND SURVIVAL (STUDY I) 
During the follow-up period (from 1987 to 1998), 958 incident cases of the following 
diseases were diagnosed: 738 (57%) cases of cardiovascular disease (CVD), 371 (28%) 
cases of dementia, and 186 (14%) cases of cancer. During a period of 16 years a total of 
1140 (87%) participants died. 
We investigated the association between survival over a period of 16 years and incident 
dementia, CVD, and cancer (Table 6). The association between dementia and mortality 
rate was similar to the association between CVD and mortality rate. The mortality rate 
among those diagnosed with dementia or CVD was approximately 2 times higher than in 
participants without those disorders. Individuals diagnosed with cancer had a 3-fold 
increased mortality rate compared with those without a diagnosis of cancer. 
 
Table 6 Adjusted hazard ratio (HR) and 95% confidence interval (CI) for the 
association between incident dementia, CVD, cancer and survival 
 HR (95% CI) 
 Basic adjustment
* 
Multivariable adjustment
* 
Incident dementia 1.77 (1.55 to 2.03) 1.69 (1.47 to 1.92) 
Incident CVD 2.21 (1.90 to 2.57) 2.07 (1.78 to 2.41) 
Incident cancer  2.92 (2.47 to 3.45) 2.71 (2.29 to 3.21) 
*
Basic adjustment: sex and education. Multivariable adjustment: sex, education, 
and baseline diagnosis of CVD and cancer.  
 
Based on hazard ratios and fraction of incidence diseases, we estimated the reduction in 
the disease-specific mortality that would be observed if the population was entirely 
unexposed to the disease. The population attributable risks were 16% for dementia, 38% 
for CVD, and 20% for cancer. 
We next estimated the mean survival time after the diagnosis of these diseases and the 
years of life lost because of premature death. Estimated years lived with incident 
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diagnoses of the 3 diseases were 4.1 with dementia, 4.2 with CVD, and 2.2 with cancer. 
The potential years of life lost were 3.4 because of dementia, 3.6 because of CVD, and 4.4 
because of cancer.  
The estimated years people lived with each disease or lost to it depended on age at 
diagnosis (Figure 9). In general the impact of dementia, CVD, and cancer on lifespan was 
higher in the youngest old group (75–84 years) than in the oldest old group (85 years and 
older). 
 
 
Figure 9 Mean survival time with and years of life lost because of incident 
dementia, CVD, and cancer stratified by age groups 
 
The actual numbers of years lived in the different severity stage of dementia were 
estimated. Individuals with dementia lived, on average, for 5 months in the very mild 
dementia stage, 23 months in the mild stage, 14 months in the moderate stage, and 12 
months in the severe stage. Women diagnosed with dementia before the age of 85 lived 
1.6 years longer in the severe stage than men. Medical records were available for those 
who died during the first (n=318), second (n=282), and third (n=202) follow-up periods. 
For those people who died before the follow-up examination, the dementia diagnosis was 
estimated using multiple imputation technique. This sensitivity analysis provided similar 
results, for instance the multivariable adjusted HR were 1.81 (1.60 to 2.05) for dementia, 
2.09 (1.80 to 2.43) for CVD, and 2.66 (2.25 to 3.15) for cancer. 
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5.2 APOE-RELATED MORTALITY (STUDY II) 
At baseline more than half of the participants had the ε3ε3 genotype, 13% had ε2ε3 
genotype, and 30% had ε4 allele. As expected, because of the effect of aging and survival 
selection, the proportion of participants with ε2ε3 genotype increased from baseline to the 
end of the follow-up time (after 18 years). This increase was followed by a concomitant 
decrease in the number of participants with the ε4 allele (Figure 10). 
 
 
Figure 10 Percentage (%) of ε2ε3 and ε4 carriers from baseline to the end of the follow-up time  
 
After 18 years of follow-up, only 95 (87%) participants were still alive. Survival curves 
for carriers of the ε2ε3 genotype and any ε4-allele were different from those of the ε3ε3 
reference group (p-value<0.001). The longer survival of carriers of the ε2ε3 genotype 
were more pronounced among the oldest old (85 years and older). After adjustment for 
gender and education, ε4-carriers had a higher mortality rate (HR=1.22, 95% CI: 1.07 to 
1.41) and ε2ε3-carriers a lower mortality rate (HR=0.72, 95% CI: 0.59 to 0.88), than the 
ε3ε3-carriers. There were so few ε2ε2-carriers in the study group that we excluded them 
from the analysis. 
The next step was to investigate whether difference in survival might be explained by the 
APOE-related diseases (dementia and IHCD) (Table 7). The results in Table 7 show that 
the association between APOE and survival was modified by dementia status but not by 
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IHCD. Moreover, the mortality rate was mainly increased for ε4-carrier men, whereas the 
inverse association between ε2ε3 genotype and survival was present only among women.  
APOE genotypes were missing for approximately one third of the study population. The 
magnitude and direction of the hazard ratios based on complete case analysis and multiple 
imputations were similar overall; the average of the relative differences for the sex- and 
education-adjusted hazard ratios was 1.8% 
 
Table 7 Adjusted HR and 95% CI by APOE genotype in the whole study population 
and by sex 
 HR (95% CI) 
 Model 1
* 
Model 1 + IHCD Model 1 + dementia 
Entire population   
     ε3ε3 Ref. Ref. Ref. 
     ε2ε3 0.72 (0.59 to 0.88) 0.77 (0.63 to 0.94) 0.76 (0.62 to 0.92) 
    Any ε4 1.22 (1.07 to 1.41) 1.24 (1.08 to 1.43) 1.08 (0.94 to 1.25) 
Men    
     ε3ε3 Ref. Ref. Ref. 
     ε2ε3 1.07 (0.73 to 1.57) 1.17 (0.79 to 1.71) 1.11 (0.76 to 1.62) 
     Any ε4 1.48  (1.11 to 1.98) 1.72 (1.27 to 2.32) 1.29 (0.96 to 1.74) 
Women    
     ε3ε3 Ref. Ref. Ref. 
     ε2ε3 0.63  (0.50 to 0.79) 0.67 (0.53 to 0.85) 0.66 (0.52 to 0.83) 
    Any ε4 1.13  (0.96 to 1.33) 1.11 (0.95 to 1.31) 1.00 (0.85 to 1.18) 
*
Adjusted for gender and education 
 
5.3 LIFESTYLE, SOCIAL NETWORK, AND SURVIVAL (STUDY III) 
We compared the association between potentially relevant modifiable factors and median 
age at death. During 18 years of follow-up, 149 (8%) participants survived and 1661 
(92%) did not. Overall, the median age at death was 90.0 years of age. 
 In the multivariable model, median age at death for women was higher than for men 
(difference in median age at death, years 2.4, 95% CI: 1.7 to 3.2). Participants whose 
weight was normal or who had never smoked lived longer than those who were 
underweight (-1.5, 95% CI: -2.4 to -0.6) and current smokers (-0.9, 95% CI: -1.9 to -0.0). 
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Participants with a high level of education (8 years or more) and those who consumed a 
moderate amount of alcohol survived a median of 9 months longer than those with low 
education (0.9, 95% CI: 0.2 to 1.7) and those who never drank (0.8, 95% CI: 0.1 to 1.6). 
Of all the leisure activities, physical activity was associated with the largest difference in 
median survival; those who were physically active survived 2 years longer than those who 
were physically inactive (2.0, 95% CI: 0.7 to 3.3). Further adjustment for multimorbidity 
attenuated the differences in median survival.  
The next step in the analysis was to combine the modifiable factors in 4 different groups: 
low risk profile, moderately low risk profile, moderately high risk profile, and high risk 
profile. The median survival of individuals with a low risk profile (healthy lifestyle 
behaviors, participation in at least 1 leisure activity, and a rich or moderate social 
network) was 5.4 years longer than those with a high risk profile (unhealthy lifestyle 
behaviors, no participation in leisure activities, and a limited or poor social network). 
Even among the oldest old (85 years and older) and individuals with chronic conditions, 
the median age at death was 4 years higher for those with a low risk profile than those 
with a high risk profile (Figure 11). 
 
 
Figure 11 Differences (in years) in median age at death for the people 
with a low risk profile compared with the high risk profile group, in the 
whole population, by sex, by age, and by health status 
 
The proportion of missing covariates data was 4% for leisure activities, 19% for BMI, 
28% for smoking, and 32% for alcohol consumption. The magnitude and direction of the 
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differences in median age at death based on the main analysis of complete data (60% of 
the cohort) and the sensitivity analysis of multiple imputation were similar.  
 
5.4 INTERPLAY BETWEEN LIFESTYLE AND GENETIC FACTORS (STUDY 
IV) 
We investigated variations in 14 candidate genes (16 SNPs) associated with diseases that 
might have an impact on lifespan or with a mechanism that might influence lifespan. 
During 20-years of follow-up period 1187 (97%) deaths occurred. Overall, 50% of the 
participants lived to be 90.6 years and older (median age at death). After controlling for 
age and gender, we found that increased mortality rate was associated with allelic 
variation in 4 genes related to cardiovascular diseases and metabolism: APOE ε4 
compared with no ε4 allele (HR=1.26, 95% CI: 1.11 to 1.44), APOC1 G-carriers 
compared with AA-carriers (HR=1.22, 95% CI: 1.08 to 1.38), IDE C-carriers compared 
with TT-carriers (HR=1.20, 95% CI: 1.06 to 1.36), and PI3K G-carriers compared with 
the AA-carriers (HR=1.12, 95% CI: 1.00 to 1.27). Gene-gene interactions were tested one 
by one while adjusting for the remaining genes associated with mortality. We did not find 
any statistical significant interaction among the genes studied.  
A binary variable was created, coded as at least 1 risk allele (alleles associated with 
increased mortality in the analyses) versus no risk alleles. Carrying at least 1 risk allele 
was associated with 24% higher mortality rate than not carrying any risk allele. However, 
individuals with at least 1 risk allele and a healthy lifestyle had substantially lower 
mortality rate than those with no risk allele and an unhealthy lifestyle (HR=0.33, 95% CI: 
0.18 to 0.62).  
Figure 12 shows the multivariable adjusted association between genetic polymorphisms 
and mortality, taking lifestyle factors into account. Individuals without any of the risk 
alleles previously found to be associated with mortality had 20% less rate of death than 
carriers of at least 1 of the risk alleles, corresponding to a difference in median age at 
death of 1 year. Healthy life habits, participating in leisure activities, and having a 
moderate or rich social network were associated with a 20–60% decreased rate of death 
and up to a 3-year increase in lifespan.  
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*
Among the following genes: APOC1, APOE, IDE (rs1887922), and PI3K 
Figure 12 Adjusted HR and differences in median age at death (years) 
according to genetic and lifestyle factors  
 
The combined absence of risk alleles and presence of healthy lifestyle was associated with 
80% lower mortality rate and 6 years longer median lifespan than the combination of at 
least 1 risk allele and unhealthy lifestyle (Table 8). 
 
Table 8 Adjusted medians age at death and 95% CI according to different 
genetic and lifestyle profiles 
 Genetic factors 
Lifestyle profiles 
At least 1 risk allele 
(n=987) 
No risk allele 
(n=168) 
Unhealthy  83.8 (81.6 to 86.0) 84.9 (82.6 to 87.2) 
Healthy 89.2 (86.5 to 91.9) 90.3 (87.7 to 92.9) 
 
We found similar magnitude and direction of associations between genetic and lifestyle 
factors in the main analysis of complete data and the sensitivity analysis of multiple 
imputations. 
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6 DISCUSSION 
6.1 SUMMARY OF THE MAIN FINDINGS 
This research project explored the association between survival and medical, lifestyle, and 
genetic factors by analyzing longitudinal data from a community-based cohort of men and 
women 75 years of age and older. The main results can be summarized as follows. 
 
6.1.1 Age-related chronic diseases 
- Of the 3 diseases studied, cancer was the most strongly associated with mortality 
when comorbidity was taken into account. A person with a cancer diagnosis had a 
3-fold higher mortality rate than a person without cancer, and 4 potential years of 
life lost.  
- The patterns of mortality associated with dementia and CVD detected were 
similar in terms of excess mortality rate (2 times higher than in those without the 
disease in question) and years of life lost (approximately 3.5 years).  
- For all 3 diseases, time from diagnosis to death tended to be shorter in those who 
were diagnosed at older ages.  
- Half the years lived with dementia were spent in the moderate and severe stages of 
the disease. 
 
6.1.2 APOE-related mortality 
- Findings suggested that APOE alleles played different roles in survival in elderly 
women than they played in elderly men. The mortality rate was 40% lower in 
women carrying the ε2 allele than in women with the ε3ε3 genotype. The ε4 allele 
was associated with 50% higher rate of death among men but not among women.  
- Dementia accounted for the majority of the increased mortality rate in those with 
the ε4 allele, but the protection associated with the ε2 allele remained after 
adjustment for dementia. 
- IHCD did not change the mortality rate among ε4- and ε2-carriers. 
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6.1.3 Lifestyle factors 
- A healthy lifestyle and a rich social network were positively associated with 
longevity among 75 years and older, prolonging their lifespan.  
- As expected, presence of a chronic disease and especially of more than 1 disease 
was associated with reduced lifespan. Current smokers died about 1 year earlier 
than non-smokers. Former smokers did not differ from those who had never 
smoked in terms of age at death. Participants who were underweight died 1 year 
earlier compared with those who weight was normal. 
- Women, as expected, lived longer than men. The median difference in lifespan 
was 2 years. A similar increase in length of life was noted in those who reported 
being physically active (walking, swimming, or exercising a minimum of once a 
month). 
- Individuals aged 75 and older who were non-smokers, participated in leisure 
activities at least once a month, and had good social support lived about 5 years 
longer than inactive smokers with poor social support. 
- One additional important finding from the study was that the negative 
association between a chronic disease and survival is moderated by a low risk 
behavioral profile. 
 
6.1.4 Lifestyle and genetic factors 
- Genetic risk factors were relevant for survival after age 75. Variations in 4 
different genes (APOC1, APOE, IDE, and PI3K) were associated with mortality. 
The higher mortality rate associated with certain alleles ranged between 12-20%.  
- The results suggest that healthy lifestyle may counteract the association between 
carrying 1 or more risk alleles and mortality. Those who carried at least 1 risk 
allele had 24% higher rate of mortality than those with no such alleles. 
Participants with at least 1 risk allele who had a healthy lifestyle, however, had 
about 70% lower rate of mortality than those with no risk allele plus an unhealthy 
lifestyle. 
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- Those with no risk alleles and a healthy lifestyle had 80% decreased mortality rate 
and 6 years longer median lifespan than people with at least 1 risk allele and an 
unhealthy lifestyle. 
 
6.2 METHODOLOGICAL ISSUES 
Different sources of systematic errors or bias are likely to occur in observational studies: 
selection bias, information bias, and confounding. It is important to evaluate the 
possible role of systematic errors when interpreting observed results. A qualitative 
discussion of potential biases in the 4 studies follows. 
 
6.2.1 Internal validity 
6.2.1.1 Selection bias 
Selection biases are distortions in the exposure-outcome association that result from 
procedures used to select participants and from factors associated with study 
participation. This type of systematic error arises when the exposure-outcome 
association is different in those who participated and all those who were eligible for the 
study, including those who did not participate.  
The Kungsholmen Project is a prospective study of a community-based cohort of people 
75 years and older drawn from a geographically defined area. The dropout rate in the 
screening phase (Phase I) of the project was 23.6% (558/2368). The main reasons for 
dropout included: refusal (12.4%), death (7.6%), and moving from the area (3.6%).
259
 
The personal characteristics of those who refused to participate and those who moved 
did not differ from those of the participants. However, the 181 who dropped out because 
they died were older than the participants and were more often men. It is likely that 
drop-outs led to an underestimation of the mortality rate and overestimation median age 
at death, especially for the oldest old men (85 years and older). In the clinical phase 
(Phase II) of the baseline survey, 110 subjects dropped out for reasons similar to the 
reasons for dropout in Phase I.  
In the analysis in Studies I-IV, we used advanced statistical methods for multiple 
imputations to evaluate the way in which missing data might affect the observed 
findings. Overall, results based on complete subjects and multiple imputed datasets 
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were very similar, suggesting that the subsample of people included in the analysis was 
a random subset of the entire study population.  
  
6.2.1.2 Information bias 
Information bias occurs whenever there are systematic errors in the assessment of the 
main variables used in the analysis.
288
 
 
Misclassification of the outcome 
Nordic countries have a long tradition of collecting data on deaths.
289
 Causes of death 
have been registered in Sweden since 1751 (records from 1952 and onward have been 
computerized). Using a unique personal identification number, the cohort was linked to 
the Cause of Death Register to identify deaths. This register provides nearly 100% 
complete case ascertainment in Sweden; therefore misclassification of the outcome 
(survival status) is unlikely. 
 
Misclassification of the exposures  
Misclassification of chronic diseases: dementia, CVD, and cancer. Bias in the 
information on incidence of chronic disease would have been an important concern if 
information about disease incidence were solely based on self-reported information. To 
minimize this type of bias, we used different sources of information on the health status 
of the participants: interview-based questionnaires, national registry data, and clinical 
examinations.  
Misclassification of lifestyle factors. A structured interview by trained nurses was used 
to obtain information on lifestyle factors such as smoking habits, alcohol consumption, 
social network, and leisure activity. If a participant was not able to answer because of 
disease at baseline, a next-of-kin was interviewed. Previous research has shown that the 
validity of structured interview assessment is higher than that of self-administered 
questionnaires.
290
 On the other hand, a possible limitation of face-to-face interviews is 
that some participants may report behaviors not entirely consistent with the reality. 
Moreover, information collected from next-of-kin might be less precise than 
information reported by the participants themselves.  
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Misclassification of genetic factors. The SNP genotyping method is based on MALDI-
TOF analysis, performed on the MassARRAY Platform from SEQUENOM. This 
technique has the potential to provide highly accurate identification of genetic variations 
in DNA samples. The first step in assessing genetic variation in DNA samples is usually 
amplification of the DNA sequences of interest using polymerase chain reaction (PCR). 
This technique is based on thermal cycling and DNA replication to obtain many copies 
of a short fragment that harbor the variation of interest. Since this is the first step in 
detecting variations, optimization of its conditions is crucial. The quality of the DNA is 
also important for this initial step. In our cohort, we collected DNA from blood samples. 
Even though the blood was stored for a long time, we could efficiently amplify the 
DNA sequences of interest using PCR, and the desired SNPs were analysed after a 
number of optimization steps. Therefore it is unlikely that we have introduced any bias 
with the genotyping method.  
 
In our prospective studies, all the exposures were assessed before the occurrence of 
death. Therefore any remaining classification errors would be independent of the future 
outcome. Non-differential misclassification of the exposure would lead most likely to 
attenuation of the observed findings.  
 
6.2.1.3 Confounding 
Confounding occurs when the observed exposure-outcome association or lack of 
association is distorted because of extraneous factors mixed with the actual exposure 
effect (which may be null). The parameters that govern the magnitude and direction of 
the bias are the confounder-exposure and the confounder-outcome associations. 
Confounding can lead to overestimation, underestimation, or even change in the 
direction of the apparent exposure-outcome association. Moreover, we could not fully 
control for bias if there are errors in the measurement of confounders. In such a case, 
residual confounding would persist. 
The epidemiology of human longevity is a particularly challenging area of research 
because longevity is affected in complex ways by genetic, environmental, and social 
factors. In the analyses, we simultaneously took into account a variety of factors (age, 
gender, educational level, history of chronic diseases, lifestyles, and genetic 
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background). We found minimal differences between findings from models of 
increasing complexity. In general, after adjustment for age and gender, the addition of 
other possible confounding factors had minor impact on the main findings. 
The strongest predictor of longevity is age, and exposures like incidence of chronic 
diseases and lifestyle may vary with age. As suggested in epidemiological literature, we 
therefore used age as the primary time scale in all models for survival analysis to better 
control for this predictor. Use of the Swedish personal identification number enabled us 
to measure the age of the participants with almost no possibility of error. 
Leisure activities, social network, and life habits can have both immediate and cumulative 
effects. Because we assessed modifiable factors only at baseline, we could not assess the 
relationships between survival and changes in modifiable factors over the lifespan. 
Furthermore, repeated measurements of exposure would have provided a better 
understanding about whether accumulation of factors over the lifetime affects the 
associations between survival and lifestyle or social factors. It is also possible that 
individuals who were active at younger ages entered old age with more favorable 
circumstances: established activity habits, a greater likelihood of a wider social network 
and beneficial health behaviors, and better health in general. These circumstances form a 
foundation that facilitates continued participation in activities, which in turn further 
promotes health.  
 
6.3 REVERSE CAUSALITY 
An important issue when studying leisure activities and social network is reverse 
causality, which suggests that the association between lifestyle factors and health is more 
strongly driven by health (which leads to greater participation in activities) than by 
activities (which lead to health). Healthier individuals tend to participate in leisure 
activities to a greater extent than those who are less healthy, and they may also be more 
inclined to participate more regularly and with greater intensity.  
Correspondingly, a socially isolated and sedentary lifestyle may affect health and well-
being negatively, which in turn would create additional barriers to engaging in activities. 
In Study III, the count of number of chronic diseases was used as a proxy for the health 
status of the participants to help control for this potential confounder.  
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6.4 INTERPRETATION OF THE FINDINGS 
The results of this project make it clear that the aging phenotype is very heterogeneous. 
Longevity was achieved in different ways and via different combinations of genetics, 
lifestyle, and health status.  
 
6.4.1 Survival and age-related chronic diseases 
Cancer and cardiovascular diseases are leading causes of death and disability among the 
elderly population.
103
 However, when compared with other age-related diseases, dementia 
emerges as the strongest determinant of functional dependence.
291
 In agreement with 
previous reports, in Study I we found that cancer had the strongest effect on mortality 
when comorbidity was taken into account.
292
 Persons who developed cancer after age 75 
had a 3-fold higher mortality rate than those without the disease and their life was 
shortened by 4 years. The association between dementia and mortality was similar to the 
association between CVD and mortality in terms of excess rate of death and years of life 
lost. The excess mortality associated with dementia that we found (HR=1.8) is in 
agreement with the results of both French
293
 and American
294
 studies but is slightly lower 
than the associations found in other community-based studies.
292,295,296
 After comorbidity 
was taken into account, the mortality rate associated with CVD was similar to that found 
in a previous report.
297
 
We also estimated the mean survival time after the diagnosis of dementia, CVD, and 
cancer. Estimated years lived after incident diagnosis was 4.15 for dementia, 4.25 for 
CVD, and 2.25 for cancer. The mean survival time after the onset of dementia estimated 
in other studies
292,293,298,299
 is similar to the estimation in our study. In general, the impact 
of dementia, CVD, and cancer on lifespan was higher among the youngest old people 
(75–84 years of age) than the oldest old group (85 years and older). 
The years lived after dementia onset are years of progressive disability, paralleled by an 
increased need for formal and informal care. In particular, women lived around 30% of 
this period in the most severe stage of dementia. 
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6.4.2 Survival and APOE 
The majority of the previous reports that have analyzed the association between APOE 
and survival have been cross sectional in design. They have found that the frequency of 
the ε4 allele is lower in older age groups (octogenarians, nonagenarians, and centenarians) 
than in younger and middle-aged people.
185,188,189,197,209,212-220
 However, the results might 
be dependent by of cohort effect. Eight reports have provided longitudinal data on APOE 
and mortality; their findings were inconsistent. Three studies did not find an 
association,
229-231
 and 5 studies found a significant association.
224-228
 The inconsistent 
results may be explained by limited sample sizes, different lengths of follow-up, and 
different age distributions in the samples studied. 
We found that the APOE gene was associated with increased rate of mortality in our 
cohort. Mortality rate was 22% higher in ε4 allele carriers than in those with the ε3ε3 
genotype, but a 28% decreased rate was observed in carriers of the ε2 allele. Adjustment 
for IHCD did not change the mortality rate among ε4 or ε2 carriers. Dementia accounted 
for the majority of the elevated mortality rate due to the ε4 allele but did not change the 
protective effect of the ε2 allele. Both effects were strongly modified by gender. Results 
suggest that men (but not women) with the ε4 allele have increased mortality rate, and 
that the ε2 allele has a relevant protective effect only in women. These gender differences 
should first be confirmed and then further explored to understand the biological 
mechanisms behind them. 
 
6.4.3 Survival and lifestyle factors 
Many factors can influence human longevity, but modifiable risk factors are especially 
relevant as they are amenable to intervention. Lifestyle, social networks, and leisure 
activities have been studied individually in relation to longevity in several studies, and 
other studies have examined the possible association of these factors with longevity while 
taking into account their coexistence and interactions.
81-92
 
Our study confirms the negative association between smoking and survival even in old 
age, an association reported in some previous studies,
89,91,94
 but not in others.
86,87,90
 We 
found that smokers had a 1-year shorter median survival than those who had never 
smoked. The pattern of survival in former smokers in the study population was the same 
as the pattern of survival in those who had never smoked. Because most former smokers 
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in the study had quit smoking 15 to 35 years before baseline (83%), it is not clear if 
quitting smoking 5 to 14 years before baseline may still be associated with mortality rate 
in elderly people, although this seems to be suggested by our results. 
The positive association between leisure activity, especially regular physical activity, and 
longevity found in our analysis confirms the results of some previous studies
90,91,94
 but not 
others.
89
 People who regularly engaged in physical activity lived 2 years more than 
sedentary people. The association between physical activity and survival was still 
significant after adjustment for illness that was present at baseline. We could not verify 
whether physical activity levels reported at baseline were important in and of themselves 
or were indicators of an individual’s lifetime history of physical activity. 
Our results on the associations between various patterns of modifiable factors and median 
age at death showed that compared with their respective high risk profile groups, men 
with a low risk profile gained more years of survival than women with a low risk profile: 
the women by 5 years and the men by 6 years. Even among those aged 85 years and 
older, the median age at death was 4 years higher if the participants had a healthy 
lifestyle, a rich or moderate social network, and engaged in at least 1 leisure activity. 
Finally, the median age at death for people with more than 1 chronic condition but who 
belonged to the group with the low risk profile was 87 years, 5 years later than for those 
with a high risk profile. 
Few studies have investigated the relationship between patterns of modifiable factors and 
survival. In these studies, lifestyle scores were generated by pooling a variety of factors, 
and the results showed a strong relationship between healthy lifestyle scores and 
survival.
93-95
 
 
6.4.4 Interplay between lifestyle, genetic factors, and survival 
Many candidate genes have been investigated in relation to survival or longevity, 
especially genes already associated with diseases that shorten life or with mechanisms 
that might influence lifespan. However, many of the positive results have not been 
replicated in additional studies. We found an association between survival and allelic 
variation in 4 genes: 2 genes strongly related to cardiovascular diseases (APOC1 and 
APOE) and 2 genes related to metabolism (IDE and PI3K). We did not found a significant 
association between any of the other genes examined and survival.  
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In previous studies, a high level of high-density lipoprotein (HDL) has been associated 
with a reduced risk of cardiovascular diseases.
300-303
 This relationship persisted into old 
age.
304-307
 Moreover, previous case-control studies showed that healthy elderly subjects 
have higher levels of HDL than healthy younger controls,
305
 which suggests that HDL 
may represent a longevity factor. We selected 5 SNPs on the basis of their association 
with levels of HDL or LDL cholesterol reported in previous studies and examined their 
possible association with mortality. Variations in 2 genes were found to be associated 
with survival: APOE and APOC1. The APOE gene is the one that was most explored in 
previous research,
171
 and findings indicated that the ε4 allele is associated with mortality. 
In agreement with these results, we found an increased rate of mortality among the ε4-
carriers, confirming our previous results. APOC1 was studied as candidate gene for 
longevity in an elderly population in Britain.
184
 This study reported a difference in the 
frequencies of the HpaI allele in elderly women and the younger women (p-value<0.05). 
No difference was observed between elderly men and younger men. In the present study 
we examined the rs4420638 SNP and found that the G-carriers had a higher mortality rate 
than the A-carriers. Since APOC1 is located on chromosome 19 in the same region as the 
APOE gene, these findings may reflect potential linkage disequilibrium between APOC1 
and APOE genes.  
In a variety of animal models from invertebrates to mammals, data indicate that aging is 
regulated by the insulin/IGF1 signal pathway.
308
 Therefore genes that encode components 
of this pathway could be involved in survival. On the basis of previous research that 
showed an association between genetic variation in IDE, IGF-1R, and PI3K genes and 
longevity,
232,309-311
 we investigated the role of these genes in longevity in our population. 
We found an increased mortality rate (20%) associated with a genetic variation in the IDE 
gene and a slight increased mortality rate (12%) was associated with any G allele of the 
PI3K gene. Mortality rate was highest for the GG genotype (20%) of the PI3K gene. The 
discrepancy in findings from different studies might be because of differences in 
experimental design, sample size, criteria used in selecting subjects, and different gene 
alleles examined. In addition, the association between polymorphisms and mortality 
might have a population-specific component; that is, it might be affected by the 
population-specific gene pool as well as by gene-environment interactions. Absence of 
association does not exclude the presence of a genetic impact.  
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Healthy lifestyle was associated with reduced rate of mortality even in those with risk 
alleles. Healthy lifestyle was of particular benefit to participants without any risk allele. 
People who carried at least 1 of the risk allele had 24% higher mortality rate than people 
without any risk alleles; however, if those with at least 1 risk allele had a healthy lifestyle, 
their mortality rate decreased. Finally, individuals without any risk allele who had a 
healthy lifestyle profile had approximately 80% less mortality rate, and a 6-year longer 
median lifespan than participants with at least 1 risk allele and an unhealthy lifestyle 
profile.  
Future studies are needed to confirm our findings and evaluate specific gene–environment 
interactions in relation to longevity. 
 
6.5 GENERALIZABILITY 
No study population can ever be fully representative of all other populations. The 
Kungsholmen Project cohort consisted of very old individuals (75 years and older) who 
lived in a geographically defined central area of Stockholm. The special features of this 
population included a high proportion of women, high educational level, and high 
proportion of persons with an office-related occupation (very few farmers or industrial 
workers). Findings from studies carried out in this population may be generalized to urban 
populations of older persons in Western countries, but some caution is needed when 
generalizing the findings to younger persons or residents of rural areas. 
 
   Conclusions 
  55 
7 CONCLUSIONS 
I. Survival beyond age 75 is strongly associated with health status. On the whole, our 
findings emphasized the malignant nature of the major age-related diseases (such as 
dementia, cardiovascular diseases, and cancer) that increase the mortality rate and 
shorten life. Persons with dementia, and especially women, spent half of their life after 
dementia diagnosis in the severe disabling stage of the disease. 
II. The association between APOE and survival is different for men than for women. The 
increased rate of mortality among ε4 carriers was present only among men and was for 
the most part explained by dementia. The reduced mortality rate associated with the 
ε2ε3 genotype, on the other hand, was present only among women and did not change 
after adjustment for both dementia and IHCD.  
III. The associations between leisure activity, not smoking, and increased survival still 
existed in those aged 75 years and older; women’s lives were prolonged by 5 years and 
men’s by 6 years. These associations, although attenuated, were still present among 
people aged 85 and older and in those with chronic conditions. Our results suggest that 
encouraging favorable lifestyle behaviors even at advanced ages may enhance life 
expectancy, probably by reducing morbidity.  
IV. Genetic risk factors were relevant to survival, but the inverse association between 
healthy lifestyle and mortality was still present among individuals who carried at 
least 1 risk allele. Participants with at least 1 risk allele and a healthy lifestyle had 
about 70% lower mortality rate than those with no risk allele and unhealthy lifestyle. 
Those with no risk alleles and a healthy lifestyle had 80% lower mortality rate and 6 
years longer median lifespan than people with at least 1 risk allele and an unhealthy 
lifestyle. 
.
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8 RELEVANCE AND IMPLICATIONS 
A century ago, the leading causes of death were tuberculosis, diphtheria, and influenza. 
Thanks to antibiotics, vaccines, and improved public health measures, those top 3 killers 
are no longer major threats to population. Nowadays, chronic age-related diseases that 
gradually disable over long periods of time are emerging as the leading health challenge 
of the 21st century. This is quite a new development in human history. Alzheimer's and 
Parkinson's diseases, type II diabetes, and other diseases associated with aging could 
approach epidemic proportions. These diseases deprive older people of their 
independence, decrease the quality of longer lives, and put a burden on families and 
public health resources.  
So far only few genetic and environmental factors have been identified as determinants of 
longevity, and the interplay between these factors is still unknown. Discovering the 
factors that play a role in longevity is an extraordinarily difficult task, but it has the 
potential to provide insights into central mechanisms of aging and disease. 
From a clinical perspective this topic is relevant because the identification of 
environmental and genetic factors that affect longevity may help to better understand age-
related diseases. From a public health perspective the possibility of identifying a group of 
individuals at risk of shorter and unhealthier lives may lead to primary and secondary 
preventative interventions. Identification of factors that may enhance life expectancy, 
probably by reducing morbidity, would have a profound impact both at the individual 
level and for societies by reducing care-related costs and suffering.  
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9 FUTURE DIRECTIONS 
This project showed that there are multiple ways to survive beyond 75 years of age and 
that these ways work even better if different components are combined. However, 
questions still remain. For example, is the diet one of the keys to longevity? How much 
does personality change lifespan? 
It would be interested to use the life-course approach to address longevity in future 
studies. The life-course approach considers the relevance of biological and social factors 
during early life, middle age, and late life to events that occur in late life, including death. 
This approach seeks to identify windows in time when exposures have their greatest 
effect on outcomes (an example is obesity at middle age, which is an important 
determinant of mortality in elderly people), and to determine whether accumulated 
exposures could have integrative or additive effects over the life course. Thus, the 
probability of survival after age 75 may not be determined in any single time period of the 
lifespan; rather, it may be a result of complex interactions between genetic susceptibility, 
biological factors, and environmental exposures experienced over the life course. The 
Swedish National Study of Aging and Care in Kungsholmen (SNACK) and the 
Cardiovascular Risk Factors, Aging, and Dementia (CAIDE) study, which follows a 
middle aged or older population, offer a rare opportunity to assess the long-term 
relationship between midlife lifestyle and mortality in older age, for which limited data 
exist. 
Finally, increasing life expectancy does not necessarily mean improved health in the 
population. Whether extra years of life gained through increased longevity are spent in 
good or bad health remains a crucial question to be explored. 
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